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Sound clinical intervention research relies on the use of the right outcomes 
dependably and without bias. This dissertation addresses important research gaps 
related to selection, specification, data colection and analysis, and reporting of 
outcomes in research. 
 
Methods 
We examined systematic reviews (SRs) and randomized controled trials 
(RCTs). For Aim 1, related to outcome selection, we conducted a case study of 
outcomes in al Cochrane SRs addressing HIV/AIDS (June 2013), to evaluate 
whether social network analysis methods could be used to identify central 
outcomes for core outcome sets. For Aim 2, related to outcome specification and 
data colection and analysis, we examined al Cochrane SR protocols (June 2013) 
addressing four major eye conditions for completeness of pre-specification and 
comparability of outcomes. For Aim 3, related to outcome reporting, we examined 
al conference abstracts of RCTs presented at the Association for Research in 
Vision and Ophthalmology (ARVO) 2001-2004 conferences to: (1) evaluate 
agreement in main outcome results comparing abstracts and coresponding ful 





For Aim 1, we applied social network analysis methods to identify central 
outcomes, and found that the most central outcomes often differed from the most 
frequent outcomes. For Aim 2, outcome pre-specification in SRs was largely 
incomplete. For Aim 3, only 44.8% of abstracts describing RCTs were published 
in ful, and more than half (54.7%) of the 86 conference abstract/ful publication 
pairs had some form of discordance in reported results for the main outcome. First 
author conflicts of interest were associated with ful publication, irespective of 
whether the main outcome results in the abstract were statisticaly significant, not 
statisticaly significant, or the statistical significance was not reported. 
 
Conclusions 
This dissertation identifies causes for concern, such as incomplete outcome 
pre-specification in SR protocols, and discrepancies in results comparing 
conference abstract/ful publication pairs of the same RCT. We suggest ways 
forward, such as use of social network analysis methods to identify central 
outcomes for core outcome sets, and incorporation of a five-element framework 
for outcome pre-specification in SR and RCT protocols. 
iv 
DISSERTATION READERS AND FINAL EXAMINATION COMMITTEE 
Kay Dickersin, PhD 
Dissertation Advisor 
Professor 
Department of Epidemiology 
Johns Hopkins Bloomberg School of Public Health 
 
Henry D. Jampel, MD 
Professor 
Department of Ophthalmology 
Johns Hopkins School of Medicine 
 
Joanne Katz, ScD 
Chair of Examination Committee 
Professor  
Department of International Health 
Johns Hopkins Bloomberg School of Public Health 
 
Roberta W. Scherer, PhD 
Senior Scientist 
Department of Epidemiology 
Johns Hopkins Bloomberg School of Public Health 
 
 
ALTERNATE COMMITTEE MEMBERS 
 
Marie Diener-West, PhD 
Professor  
Department of Biostatistics 
Johns Hopkins Bloomberg School of Public Health 
 
Janet T. Holbrook, PhD 
Associate Professor 
Department of Epidemiology 
Johns Hopkins Bloomberg School of Public Health 
  v 
ACKNOWLEDGEMENTS 
 Completing a PhD is a labor of love. One has to love a topic enough to 
spend the requisite time, money, and efforts to pursue it in depth. For me, arriving 
at my topic (outcome use in clinical intervention research) involved the confluence 
of two phases of my academic life: my clinical training and my research training. I 
have many to thank for helping me realize this love, formulate it into a 
dissertation, and complete the dissertation successfully.   
 I am most thankful for my PhD advisor Dr. Kay Dickersin. Words fail to 
capture how exceptional a mentor, teacher, and role model she is; but, I am going 
to try. Kay is a perfectionist, and has taught me to never accept mediocrity. She 
has always been patient and believed in me while I developed and worked through 
my research ideas. She has always encouraged me to think big, but to be detail-
oriented and concerned about methods. One of the skills I have developed during 
my PhD is scientific writing. Much of this development has come from writing 
collaboratively with Kay. For example, I have learned from Kay to never 
underestimate the value of telling a clear and coherent story. I am also very 
thankful to Kay for numerous exciting opportunities, such as building connections 
with local, national, and international collaborators, and finding funding for my 
research and professional travel. One such example was when Kay and I 
developed the Collaborative Outcomes Study of Meta-analyses in HIV/AIDS 
(COSMAHA), based at the South African Cochrane Centre in Cape Town, South 
Africa. Funded through the Johns Hopkins Center for Global Health and Kay’s 
  vi 
discretionary funds, I was able to spend two months in Cape Town, collaborating 
with members of the South African Cochrane Centre and the Cochrane Review 
Group on HIV/AIDS (both based in Cape Town). This project, besides providing 
the data for Aim 1 of my dissertation, helped me expand my international network 
of collaborators, something that will definitely be invaluable to me in the future.  
 Before I started my PhD in 2011, I worked for about five years with Dr. 
Karen Robinson at the Johns Hopkins School of Medicine. Karen is a true 
inspiration and a professional par excellance. It is from working with her and 
others at the Johns Hopkins Evidence-based Practice Center (EPC) that I fell in 
love with systematic reviews and the methods used to conduct them. She was very 
supportive of me applying for a PhD and has been a wonderful mentor, always 
encouraging me to aim higher! 
 I am very thankful for the members of my PhD dissertation committee: Drs. 
Kay Dickersin, Roberta Scherer, and Marie Diener-West. They have been 
incredibly supportive. I also thank all members and alternate members of my 
departmental and school-wide preliminary oral examination committees (Drs. 
Marie Diener-West (Chair), Kay Dickersin, Roberta Scherer, Stephan Ehrhardt, 
Henry Jampel, Karen Robinson, Janet Holbrook, Joanne Katz, and Lawrence 
Moulton) and all thesis readers and members and alternate members of my final 
oral examination committee (Drs. Joanne Katz (Chair), Kay Dickersin, Roberta 
Scherer, Henry Jampel, Marie Diener-West, and Stephan Ehrhardt). The questions 
  vii 
that I was asked and the suggestions I received during these examinations were 
incredibly thoughtful and useful.  
 One of the unwritten prerequisites of PhD programs is a love for learning. 
During my program, I have enjoyed learning from a number of phenomenal 
teachers. Teachers at the Bloomberg School of Public Health do not just teach; 
they inspire. I am indebted to each one of them for pushing me to greater things, 
both during courses that I took and those that I assisted with teaching. I am also 
very thankful for everything that I have learned from various faculty members, 
staff, and fellow students in the Department of Epidemiology, the Center for 
Clinical Trials and Evidence Synthesis, and the Cochrane Eyes and Vision Group 
US Satellite – Dr. Kay Dickersin, Dr. Tianjing Li, Dr. Roberta Scherer, Dr. 
Barbara Hawkins, Dr. Swaroop Vedula, Dr. Evan Mayo-Wilson, Dr. Susan 
Hutfless, Dr. Asieh Golozar, Mrs. Kristina Lindsley, Dr. Shilpa Viswanathan, Mrs. 
Nicole Fusco, Ms. Gillian Gresham, Mr. Jimmy Le, and many others. At 
numerous research-in-progress meetings and journal clubs, they have listened 
patiently and provided important constructive criticism as I bounced off ideas and 
presented my findings. They have always done so with a smile, and have taught 
me to love my work and everything around it to the fullest extent!  
 I am very grateful for Mrs. Frances Burman and others in the Academic 
Support Core in the Department of Epidemiology. Fran is an extraordinarily 
valuable resource to everybody in our department. She is very knowledgeable 
  viii 
about most administrative issues students need help with, and her door is always 
open. 
Pursuing one’s PhD at the Johns Hopkins Bloomberg School of Public 
Health is not cheap. I am very grateful for the funding support and research 
assistantship that I have received from the Cochrane Eyes and Vision Group US 
Satellite and the National Eye Institute, without which pursuing a four year 
program of this nature would have been almost impossible. I am grateful for the 
generosity of donors of the Department of Epidemiology awards – the Dorothy 
and Arthur Samet Student Support Fund award and the Miriam E. Brailey Fund 
award. I also am grateful for conference travel support from the Cochrane Eyes 
and Vision Group, the Center for Clinical Trials and Evidence Synthesis, the 
Center for Global Health, the Department of Epidemiology, and the Johns 
Hopkins Bloomberg School of Public Health Student Assembly. I am also 
thankful for the Thomas C. Chalmers Award for Best Oral Presentation at the 22nd 
Cochrane Colloquium.  
 As much as I have loved working on my PhD, we all need our outlets to 
unwind and re-charge. I am very thankful for my family and close friends, both 
near and far, for providing this to me. They are too numerous to name here, but 
each contributed greatly. I confide in them, draw my energy from them, and love 
them dearly. My friends in Baltimore and my brothers Carl and Terence deserve 
special mention. Being the youngest of three brothers who lost their parents 
relatively young, I have always felt loved and cared for by my brothers. Day or 
  ix 
night, they are always a phone call away, willing to lend an ear while I vent, and 
provide unflinching support and encouragement. 
 Last, and certainly not the least, I am eternally grateful for my late parents 
Lolita and Sylverius Saldanha, whom I loved to no end. While I could write a 
whole book about them and the inspiration they provided, not a word of this 
dissertation book would have been written if it were not for them. I am because 
they were. My mother Lolita deserves special mention because a few months after 
she retired as a professor at age 60, she began her own PhD program in Education 
at the University of Mumbai, something she had always regretted not doing. 
However, she never let retirement come in the way of an unfulfilled dream. 
Unfortunately, death came in the way two years later, even before her preliminary 
oral examination. 
To my mother Lolita and my father Sylverius: this one’s for you! 
x 
TABLE OF CONTENTS 
Page 
Dissertation Abstract ......................................................................................... ii 
Dissertation Readers and Final Examination Committee ................................ iv 
Acknowledgements ........................................................................................... v 
Table of Contents .............................................................................................. x 
List of Abbreviations ........................................................................................ xi 
List of Tables ................................................................................................... xii 
List of Figures ................................................................................................. xiv 
Chapter 1 – Introduction .................................................................................... 1 
Chapter 2 – Aim 1 ........................................................................................... 35 
Chapter 3 – Aim 2 ........................................................................................... 84 
Chapter 4 – Aim 3 ......................................................................................... 122 
Chapter 5 – Conclusions ................................................................................ 175 
Curriculum Vitae ........................................................................................... 185 
 
xi 
LIST OF ABBREVIATIONS 
 
• AHRQ = Agency for Healthcare Research and Quality  
• AMD = age-related macular degeneration 
• ARVO = Association for Research in Vision and Ophthalmology  
• CENTRAL = Cochrane Central Register of Controlled Trials  
• CER = comparative effectiveness research  
• CEVG = Cochrane Eyes and Vision Group  
• CI = confidence interval  
• COMET = Core Outcomes Measures for Effectiveness Trials 
• CONSORT = Consolidated Standards of Reporting Trials 
• CRD = Centre for Reviews and Dissemination  
• CRG = Cochrane Review Group  
• DR = diabetic retinopathy  
• ICTRP = International Clinical Trials Registry Platform  
• IOM = Institute of Medicine  
• IQR = interquartile range 
• iQWiG = Institute for Quality and Efficiency in Health 
• IRB = Institutional Review Board  
• LILACS = Latin American and Caribbean Health Sciences Literature  
• nNBC = normalized node betweenness centrality  
• OMERACT = Outcome Measures in Rheumatology  
• PCORI = Patient-Centered Outcomes Research Institute  
• PICO = population, intervention, comparison, outcomes 
• PRISMA = Preferred Reporting Items for Systematic Reviews and Meta-
analyses 
• PRISMA-P = Preferred Reporting Items for Systematic Reviews and Meta-
analyses Protocols  
• PROMIS = Patient-Reported Outcomes Measurement Information System  
• QALYs = quality-adjusted life years 
• RCT = randomized controlled trial 
• RR = relative risk 
• SRDR = Systematic Review Data Repository 
xii 
LIST OF TABLES 
 
Number Table Title Page 




2-2 (Chapter 2, Table 2) Comparison of seven most central and 




2-3 (Chapter 2, Table 3) Social network statistics for all 
interventions and by type of intervention (sorted by increasing 
network density)   
 
74 
3-1 (Chapter 3, Table 1) Number of protocols and outcome domains 




3-2 (Chapter 3, Table 2) Completeness (number of completely-
specified elements out of five possible) by outcome domain 
 
113 
3-3 (Chapter 3, Table 3) Completeness (number of completely-








3-5 (Chapter 3, Table 5) Frequency of categories of specific metric 
(element 3) and method of aggregation (element 4) across 
instances of usage of outcome domains by condition 
 
116 
4-1 (Chapter 4, Table 1) RCT characteristics, author characteristics, 
and main outcome results of abstracts of RCTs presented at 
ARVO conferences during years 2001-2004, overall and by 
whether or not the abstract was published in full 
 
163 
4-2 (Chapter 4, Table 2) Differences in authorship order comparing 





Number Table Title Page 
4-3 (Chapter 4, Table 3) Associations between conflicts of interest 
of authors of abstracts of RCTs presented at ARVO conferences 
during years 2001-2004 and likelihood of full publication of 
those abstracts, overall model (model 1) and interaction model, 
stratified by statistical significance of results for the main 





LIST OF FIGURES 
 
Number Figure Title Page 
1-1 (Chapter 1, Figure 1) Conceptual framework demonstrating the 
four main steps of using outcomes in a clinical intervention 
study (clinical trial or systematic review) 
 
34 
2-1 (Chapter 2, Figure 1) Categorization of all 294 unique outcomes 
into 14 categories 
 
76 
2-2 (Chapter 2, Figure 2) Exploratory social network analysis of 
156 unique outcomes that co-occurred with at least one other 
outcome in two or more systematic reviews (color-coded by 
category of outcome) 
 
78 
2-3 (Chapter 2, Figure 3) Main social network analysis of 156 
unique outcomes that co-occurred with at least one other 
outcome in two or more systematic reviews (color-coded by 
category of outcome) 
 
79 
2-4 (Chapter 2, Figure 4) Subgroup analysis - By type of 
intervention (clinical management [2-4a]; biomedical 




3-1 (Chapter 3, Figure 1) - Examples of extent of overlap of 




3-2 (Chapter 3, Figure 2) Five elements of a completely specified 
outcome, with anxiety as an example 
 
119 
3-3 (Chapter 3, Figure 3) Completeness of specification of outcome 
elements, by outcome 
 
120 
3-4 (Chapter 3, Figure 4) Completeness of specification of outcome 
elements, by condition 
 
121 
4-1 (Chapter 4, Figure 1) Abstracts presented at ARVO conferences 
during years 2001-2004 
 
168 
   
xv 
Number Figure Title Page 
4-2 (Chapter 4, Figure 2) Kaplan-Meier plots showing time to full 
publication of abstracts of RCTs presented at ARVO 
conferences during years 2001-2004, overall and by various 
study characteristics, author characteristics, and statistical 
significance of main outcome results 
 
169 
4-3 (Chapter 4, Figure 3) Amount of agreement in main outcome 
results in 86 pairs of conference abstracts and full publications. 
Exact agreement (green), qualitative discordance (yellow), and 
various categories of quantitative discordance (blue) are 
depicted under two different definitions of agreement – exact 




4-4 (Chapter 4, Figure 4) Unadjusted associations between 
statistical significance of results for the main outcome in 
abstracts of RCTs presented at ARVO conferences during years 
2001-2004 and likelihood of full publication of those abstracts. 
Results of observed results and hypothetical analyses are 
presented under five different assumptions about the proportion 
of abstracts with statistical significance of results for the main 
outcome among abstracts not reporting statistical significance 















Outcomes matter. In clinical intervention research, outcomes are events or 
measures in study participants that are used to assess the effectiveness and/or 
safety of the intervention being studied.[1] In other words, whether or not an 
intervention is deemed to be effective and safe is chiefly determined by the 
outcomes examined and reported in the studies informing the intervention’s use. 
Randomized controlled trials and systematic reviews of randomized controlled 
trials are the studies that provide the strongest form of evidence for or against the 
effectiveness of clinical interventions.[2] Outcomes make up a critical component 
of research questions in clinical trials and systematic reviews. In formulating 
research questions, researchers define the population, intervention, comparison, 
and outcomes (PICO) to be examined.  
While the criticality of outcomes to research has been recognized for a 
while, in recent years increased attention has been paid to the fact that research 
should examine outcomes that patients consider important. The motivation behind 
this increased attention is that those who receive an intervention (patients) should 
know how the intervention might affect them in ways that they care about. With 
this in mind, the Patient-Centered Outcomes Research Institute (PCORI) was 
established in the United States as part of the Affordable Care Act of 2009 to fund 
comparative effectiveness research (CER). The Institute of Medicine defines CER 
as “generation and synthesis of evidence that compares the benefits and harms of 
alternative methods to prevent, diagnose, treat, and monitor a clinical condition or 
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to improve the delivery of care”.[3] Much of PCORI’s efforts have focused on 
ensuring that outcomes important to patients are examined and reported in 
research.[4]  
 
2. Conceptual framework for outcome use in clinical intervention research 
The process of using the right outcomes in clinical intervention research 
has four main steps - outcome selection, outcome specification, data collection and 
analysis, and outcome reporting (see Figure 1-1). Each step has its own set of 
important considerations. 
 
2.1 – Step 1: Selection of outcomes for a clinical intervention study 
The first step in using outcomes in a clinical intervention study is to select 
the right outcomes to examine. This step helps determine whether the intervention 
being evaluated is considered to be effective and safe.  
2.1.1 – Considerations during selection of outcomes for a clinical intervention 
study 
Clinical intervention researchers generally consider a number of factors in 
selecting outcomes for their studies. These factors include relevance of the 
outcomes to clinical practice; importance to patients; importance to policy-makers; 
measurability and implementation issues; and costs and feasibility (e.g., timing 
and number of visits required to capture changes in the outcome).[5-7]  
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 Clinical relevance of outcomes is generally considered by those designing 
clinical trials and systematic reviews. For many conditions, a patient’s response to 
a clinical intervention could manifest in a variety of ways. To capture the various 
effects of a clinical intervention on symptoms and signs, physiological  
measurements, biomarkers, and adverse events, researchers may examine 
numerous outcomes among participants.[8] It is important that the outcomes 
examined capture both how effective (efficacy outcomes) and how safe (safety 
outcomes) the intervention is. Knowledge of results pertinent to both types of 
outcomes is critical in determining whether the possible benefits of the 
intervention outweigh the risks. 
Clinical intervention researchers and those who fund research often 
consider certain outcomes useful because they can shorten the duration of a trial or 
follow-up. These outcomes are known as interim outcomes because they are 
assumed or hypothesized to be on the causal pathway to a more clinically-relevant 
outcome (e.g., CD4 counts in HIV-positive patients). Because it is often not 
known for certain whether interim outcomes are on a causal pathway or are simply 
risk factors (e.g., high intraocular pressure as a risk factor for glaucoma), these 
interim outcomes are often termed surrogate outcomes. 
 Given the importance of the patient perspective, clinical intervention 
researchers are increasingly being encouraged to include more outcomes important 
to patients. Patient-important outcomes, also known as patient-centered 
outcomes,[4] are outcomes that patients value directly (e.g., relief from 
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symptoms), which often contrast with physiological outcomes that clinicians 
might consider relevant but patients feel are of less immediate concern or not 
meaningful (e.g., intraocular pressure).[9] Other examples of patient-important 
outcomes include confidence in driving at night or fatigue. In addition, 
effectiveness and safety might be of different importance among patients (for 
example, depending on a patient’s age and perceived severity of the disease), or 
between clinicians and patients. 
The preferences of policymakers and healthcare payers also may be 
considered when selecting outcomes. They are generally interested in an 
intervention’s cost and cost-effectiveness (e.g., quality-adjusted life-years 
(QALYs)). 
 
2.1.2 – Value of core outcome sets 
Depending on the various considerations described above, different 
researchers might reasonably arrive at different sets of outcomes. Such variation in 
outcomes across studies evaluating a clinical intervention’s effectiveness and 
safety makes it challenging to determine what intervention works best for a certain 
condition.[10] For example, hundreds of measurement scales have been used to 
assess mental status [11] and quality-of-life,[12] making meaningful comparisons 
across studies challenging. Such variation also threatens credible evidence 
synthesis, both looking at a single intervention and across interventions for a 
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single condition, affecting clinicians, patients, clinical practice guideline 
developers, and systematic reviewers.  
Efforts to promote comparability of outcomes across related studies in a 
field have led to the creation of core outcome sets.[13-15] One such effort is the 
Core Outcomes Measures for Effectiveness Trials (COMET) Initiative. COMET, 
launched in 2010, endeavors to develop methods for and collate core outcome sets. 
COMET defines core outcome sets as the minimum outcomes that should be 
examined in all clinical trials addressing a given condition.[16] 
 
2.1.3 – Limitations of current approaches to developing core outcome sets 
While core outcome sets could be immensely valuable, current approaches 
to develop them vary. A recent systematic review found a variety of disparate 
approaches to developing core outcome sets, including semi-structured group 
discussions (e.g., workshops), unstructured group discussions, literature reviews, 
and surveys.[17] The authors of that systematic review report on the lack of a 
current best practice, and suggest that the credibility of a core outcome set depends 
on the use of sound methods. Because systematic methods to identify core 
outcome sets are variable, it stands to reason that the outcomes selected are 
inconsistent across clinical trials and systematic reviews. In a recent study in the 
field of pre-term births, more than one-third of the 174 systematic reviews and 
more than one-third of the 1041 clinical trials studied did not examine chronic 
lung disease, a major clinical outcome relevant to that patient population.[18]  
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The clinical intervention research community is interested in identifying the 
“best” approach to developing core outcome sets.[17] In Aim 1 of this dissertation, 
we examine whether a new application of an existing method from the social 
sciences, social network analysis, can be used to identify central outcomes, which, 
in turn, could be used to develop core outcome sets (see objective and specific 
aims of this dissertation, page 21). Central outcomes refer to outcomes that are 
important to connecting other outcomes in a network of outcomes. 
 
2.1.4 – Social network analysis as a method to identify central outcomes for core 
outcome sets 
Social network analysis is the study of graphs as representation of 
relationships and patterns of interaction among nodes within a network.[19] The 
methods for social network analysis, with their basis in network theory,[20] have 
increasingly been applied to health-related research. Some of these applications 
include evaluating collaboration among researchers in cardiovascular cohort 
studies;[21] evaluating scholarly citation patterns in Alzheimer’s disease;[22] and 
evaluating the associations between personal relationships (e.g., spouses, friends) 
and happiness,[23] depression,[24] food choices,[25] physical activity,[26] alcohol 
consumption,[27] marijuana use,[28] and smoking.[29-31]  
Social network analysis provides methodological tools that could be used to 
understand patterns of co-occurrence of outcomes in a given field. The various 
outcomes examined within a group of related clinical trials or systematic reviews 
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constitute a network of outcomes. When a single study examines more than one 
outcome, outcomes (or nodes) are said to co-occur. All these outcomes might be 
examined within a network of clinical trials or systematic reviews, but not 
necessarily within a single clinical trial or systematic review. Understanding the 
affinity (or repulsion) between certain outcomes that results in their co-occurrence 
(or not) would help identify outcomes that are considered central (i.e., more 
important relative to other outcomes in a network) to a network of outcomes in 
clinical trials or systematic reviews. These central outcomes could then be used, in 
tandem with frequent outcomes, as a starting point for developing core outcome 
sets. To our knowledge, social network analysis methods have not been used to 
identify central outcomes for core outcome sets. 
 
2.2 – Step 2: Specification of outcomes for a clinical intervention study 
2.2.1 – Importance of complete pre-specification of outcomes in clinical 
intervention research 
 Once an outcome is selected for use in a clinical intervention study, the 
next step is completely specifying the outcome before the study is started. Pre-
specification of outcomes is important for a number of reasons. First, it promotes 
transparency and reproducibility of the research process. Second, when outcomes 
are pre-specified, others can learn whether the authors have selectively reported 
the study outcomes, which can result in bias if reporting is based on the direction 
of the results (outcome reporting bias).[32-35] Third, pre-specifying outcomes 
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helps researchers plan the study, measure and analyze the data, and report results 
for all outcomes that they consider important, thereby minimizing waste of 
resources on outcomes that they will not use. Indeed, pre-specification of 
outcomes at the protocol stage has been recommended for both clinical trials [36, 
37] and systematic reviews.[38-40]  
 
2.2.2 – How should outcomes be specified in clinical intervention research?  
Complete specification of an outcome (for example, in a study protocol) 
involves more than just specifying what outcomes will be examined during a 
clinical intervention study. It is also important to specify how and when the 
outcome will be examined during the study. ClinicalTrials.gov, an online register 
of ongoing clinical trials, recommends that clinical trialists specify each outcome 
using four elements - (1) the domain or outcome title; (2) the specific 
measurement or technique/instrument used to make the measurement; (3) the 
specific metric or format of the outcome data from each participant that will be 
used for analysis; and (4) the method of aggregation or how data from each group 
will be summarized.[37] In addition, the time-points that will be used for analysis 
must be specified.[37] For example, consider the common ophthalmologic 
outcome visual acuity (domain). The clinical trialist might choose to use the 
Snellen chart (specific measurement) to measure visual acuity as a change from 
baseline (specific metric). Finally, the clinical trialist might be interested in 
combining visual acuity data from individual participants in each arm of the trial 
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using the mean (method of aggregation) at 6 months (time-point). Clearly, it is 
possible that the study results presented for the outcome visual acuity might be 
different if using a 12 month time-point of outcome measurement instead of 6 
months, or if the value of mean Snellen visual acuity at one of those time-points is 
used as specific metric instead of change in mean Snellen visual acuity from 
baseline. 
 
2.2.3 – Current state of outcome specification in clinical intervention research 
 Despite existing recommendations on how outcomes should be examined 
and reported in clinical intervention research,[36, 38, 40, 41] complete pre-
specification of outcomes in clinical trials is unsatisfactory. Zarin et al. reported 
that among 100 randomly-selected clinical trials registered on ClinicalTrials.gov, 
only the domain was pre-specified for 36% of outcomes; only the domain and 
specific measurement were specified for 25%; and only the domain, specific 
measurement, and specific metric were specified for 26%.[37] 
 We also know that it is currently unclear how systematic reviewers select 
outcomes, and to what extent the outcomes they select are pre-specified. While 
formulating the research question for a systematic review, the systematic reviewer 
defines the PICO to be examined. Studies eligible for a systematic review address 
the review question and are broadly similar with regard to the population, 
intervention, and comparison groups. However, the studies included in the 
systematic review frequently report different outcomes from one another and those 
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chosen by the systematic reviewer.[18] If authors of systematic reviews 
change which outcomes are designated as primary or secondary based on the 
results in the included studies, this can lead to biased reporting of findings in 
systematic reviews.[42] 
The research community must agree on three important related issues - (1) 
how outcomes should be selected for a systematic review (e.g., should they reflect 
the outcomes in clinical trials or should the systematic reviewer select outcomes 
de novo?); (2) a core outcome set that should be examined and reported in all 
clinical trials and systematic reviews in a field (assuming this set is updated as 
needed); and (3) the elements necessary for complete pre-specification and 
reporting of outcomes.  
In Aim 2 of this dissertation, we study a sample of Cochrane systematic 
reviews addressing four major eye conditions (glaucoma, cataract, age-related 
macular degeneration (AMD), and diabetic retinopathy (DR)). We study these 
systematic reviews to examine aspects of items (2) and (3) above - completeness 
of outcome pre-specification and comparability of outcomes (see objective and 
specific aims of this dissertation, page 21). 
 
2.3 – Step 3: Data collection and analysis of outcomes in a clinical intervention 
study 
 After pre-specifying the outcomes to be examined, clinical researchers 
implement their plans, collecting and analyzing the data. Important considerations 
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include minimizing measurement error (information bias), missing data, and bias 
in the analysis. These considerations, while vital to the validity and reliability of a 
clinical intervention study, are not the direct focus of this dissertation. However, 
complete pre-specification (as discussed in step 2), helps minimize the potential 
for missing data and biased analysis.   
 
2.4 – Step 4: Reporting of outcomes from a clinical intervention study 
 The two main considerations when reporting findings from a clinical 
intervention study are reporting dependable results and avoiding reporting bias. 
 
2.4.1 – Reporting dependable results 
Researchers should strive to report results transparently, accurately, and 
dependably, whatever the forum. Dependability of reported results is 
compromised when discrepancies exist in results for the same outcome in various 
documents (e.g., protocol, trial registry entries, full publication) of the same 
clinical trial. Such discrepancies call the validity of the clinical trial and the 
veracity of its reports into question.  
Reported results of clinical trials are generally available as published 
journal articles and/or from unpublished sources (i.e., grey literature). Among 
unpublished  sources of clinical trial results, conference abstracts are the most 
important.[43] For one, although there have been recent advances related to open 
access to findings of scientific research,[44] only about 20% of the scientific 
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literature is available freely as open access material.[45] This increases the value 
of information presented at conferences, especially for individuals, such as 
community-based clinicians or those in resource-poor settings, who might not 
have access to publications requiring paid access (e.g., a journal subscription).  
Research has documented discrepancies in reported results between 
conference abstracts and corresponding full publications. For as many as 40%-
60% of clinical trials in the fields of orthopedics,[46, 47] cardiology,[48] 
pediatrics,[49] pediatric surgery,[50] and infectious disease,[51] discrepancies 
exist comparing results reported in conference abstracts and full publications.  
That discrepancies exist to this extent is troubling for two main reasons. 
First, clinical decisions are sometimes based solely on results presented as 
conference abstracts.[50, 52, 53] For example, Gross and colleagues demonstrated 
that pre-publication dissemination of results promptly led to substantial changes in 
clinical practice associated with carotid endarterectomy.[52] Second, it is 
recommended that systematic reviewers include results reported only in 
conference abstracts.[3, 38, 40] If what is reported in conference abstracts is not 
accurate, then inclusion of the data is worrisome.  
In the first part of Aim 3 of this dissertation, we examine the amount of 
agreement in main outcome results between conference abstracts and 
corresponding full publications for the same clinical trial (see objective and 
specific aims of this dissertation, page 21). To our knowledge, this has not been 
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previously examined using a large sample of randomized controlled trials in 
ophthalmology.  
2.4.2 – Avoiding reporting bias 
 Ideally, all outcomes measured in a clinical intervention study are analyzed 
(“results”) and reported by the study investigators. In clinical trials, under-
reporting of results has been called “scientific misconduct”.[54-57] Because 
clinical trial participants volunteer to participate in clinical trials with the 
understanding that their participation advances science, under-reporting is a 
violation of that understanding.[55, 57-59] Indeed, this is embodied in the general 
principles of the Declaration of Helsinki which states, “Researchers have a duty to 
make publicly available the results of their research on human subjects and are 
accountable for the completeness and accuracy of their reports”.[59] 
Under-reporting of results from clinical trials does not lead to bias per se if 
the results under-reported are a random subset of all existing results. However, 
when the nature and direction of the results influences their reporting, this is called 
reporting bias [38, 58] or, more broadly, dissemination bias.[35] As part of this 
dissertation, we focus on two distinct but related reporting biases - publication 






2.4.2.1 – Publication bias 
Publication bias refers to the tendency among researchers, peer reviewers, 
and journal editors to submit or accept manuscripts for publication based on the 
direction or strength of the study results.[35, 58, 60, 61]  
Conference abstracts are subject to publication bias, which is worrying if 
they are used as a source of evidence by decision makers and systematic reviewers 
(e.g., when these individuals do not have access to a full publication or when study 
findings have not been published in full). Conference abstracts describing 
statistically significant treatment effects or those with positive results are more 
likely to be published in full.[35, 57, 62] In a Cochrane systematic review, Scherer 
et al. reported that conference abstracts of clinical trials with positive results were 
18% more likely to be published in full.[57] Even when there is a full publication, 
presentation at a conference has been shown to be associated with delays in 
publication,[63] and clinical trials with positive results have been shown to be 
published in full sooner than those without positive results (i.e., time lag bias).[64-
66] Trial quality and sample size have also been shown to be associated with full 
publication.[57] 
Research has also shown that among clinical trials presented at conferences, 
clinical trials funded by industry are more likely to reach full publication than 
those not funded by industry.[57] The small number of conference abstracts 
reporting funding source, statistical significance of the findings (in terms of the 
association between the intervention and primary outcome examined), and 
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information about whether they reached full publication made it impossible to 
examine how positive findings are related to the apparent influence of funding on 
full publication. Among published clinical trials, clinical trials funded by industry 
are more likely than non-industry funded clinical trials to report results favoring 
the funder.[67-70] It would be interesting to see whether this relationship is also 
present in the case of full publication of conference abstracts. 
The impact of study investigators’ conflicts of interest on publication is 
even less clear. Conflicts of interest refer to the set of conditions in which 
professional judgment concerning a primary interest (such as a patient’s welfare or 
the validity of research) might be unduly influenced by a secondary interest (such 
as financial gain).[71, 72] 
In published clinical trials, the presence of financial conflicts of interest has 
been shown to be associated with greater likelihood of the authors’ conclusions 
favoring experimental interventions.[73] However, the impact of author conflicts 
of interest on study publication itself appears complex. On one hand, financial 
gain might threaten impartial judgment,[74] leading to study authors selectively 
publishing studies (publication bias [35,60, 61]), delaying publication of studies 
(time lag bias [64-66]), or selectively reporting certain outcomes (outcome 
reporting bias [32-35, 75]), based on the nature and direction of the results. On the 
other hand, having a financial relationship with industry, and the consequent 
incentives, might work to facilitate publication, irrespective of the direction of 
study results. Currently, a knowledge gap exists as to what the association is 
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between clinical trial author conflicts of interest and full publication of results, and 
whether direction of results has any bearing on this association. In the second part 
of Aim 3, we address this gap by examining the association between author 
conflicts of interest and full publication of results of clinical trials presented as 
conference abstracts (see objective and specific aims of this dissertation, page 21). 
 
2.4.2.2 – Outcome reporting bias 
 Outcome reporting bias typically is manifested by an overestimation of 
treatment effects.[32-35, 75-78]  
There are three main scenarios under which outcome reporting bias can 
occur. Each of these scenarios may be due to deliberate attempts to obfuscate or 
due to a genuine belief that the action is acceptable, or reasons between these two 
extremes. First, outcome reporting bias can occur because of selective outcome 
reporting, i.e., selective reporting on the basis of the results of a subset of the 
original pre-specified outcomes.[34, 78] Second, outcome reporting bias can occur 
when what is reported to be the primary outcome in the publication is different 
from the pre-specified primary outcome. This might be done to provide emphasis 
to a certain statistically significant or favorable non-primary outcome by making it 
the primary outcome.[79] Research has shown that for between 33% and 67% of 
clinical trials, the primary outcome in the protocol differed from that in the final 
publication,[33, 34, 75, 78, 80] and that for 31% of clinical trials the primary 
outcome changed between trial registration and publication.[79] Changing of 
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primary outcomes, addition of new outcomes in the full publication, and deletion 
of outcomes presented in the conference abstract may all occur as a consequence 
of statistical significance of results of specific outcomes.[57] Third, outcome 
reporting bias can occur even if all outcomes are reported, but the level of detail 
reported for outcomes depends on the statistical significance of the results. For 
example, in a sample of 101 clinical trials evaluated by the Institute for Quality 
and Efficiency in Health (iQWiG), publicly available sources had complete 
information on only 39% of outcomes.[81] In a random sample of 283 Cochrane 
systematic reviews, for more than half the reviews (55%), the review authors 
could not include full data for the review primary outcome of interest from all 
eligible clinical trials.[82] Studies that have compared the results of meta-analyses 
based on published data with individual patient data meta-analyses addressing the 
same research question have found that, compared with using individual patient 
data, using only published data provides up to three times larger effect estimates 
and, in some instances, leads to qualitatively different conclusions.[83-85] 
Taken together, both parts of Aim 3 address two important related issues. In 
the first part, we examine whether conference abstracts are dependable, especially 
in scenarios where a conference abstract is not published in full or if the full 
publication is not found. In the second part, we address a specific publication bias 
issue - whether author conflicts of interest are associated with a conference 
abstract reaching full publication.  
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2.4.3 – Advantages and disadvantages of including data from conference 
abstracts in systematic reviews 
Systematic reviewers strive to be comprehensive in their endeavor. 
However, the validity of the results obtained and the strength of the conclusions 
made in systematic reviews are affected by the potential for reporting biases and 
the dependability of reported data in the included studies. Including results from 
conference abstracts promotes comprehensiveness in the systematic review 
process, but systematic reviewers should recognize the advantages and 
disadvantages of including data from conference abstracts.  
Including conference abstracts has some important advantages. Conference 
abstracts can represent the most recent research results, thus providing systematic 
reviewers access to clinical trial results that might not yet be available elsewhere. 
In some instances, conference abstracts might be the only ever available source of 
information about a clinical trial (e.g., if the results are never published in full or 
are published in full in a language or database that is not accessible to the 
systematic review authors).  
Including conference abstracts in systematic reviews has its disadvantages, 
however. First, abstracts submitted for presentation at conferences typically do not 
undergo peer review. Peer review refers to the use of experts, or author peers, to 
help judge the value of submitted work.[86] These experts or peers critically 
evaluate the creative work by others in the same field. Second, conference 
abstracts often contain preliminary results and do not include final analyses. 
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Results from preliminary and final analyses might differ, especially if the 
preliminary analysis is based on a subset of the entire study population or if 
additional analyses are subsequently conducted. Third, systematic reviewers need 
to guard against “double counting” results of clinical trials presented both as 
conference abstracts and full publications. This could occur if systematic 
reviewers fail to identify a conference abstract and a full publication as addressing 
the same clinical trial, either because the reported information (e.g., clinical trial 
registration number, authors, sample size, intervention details) differs in the two 
documents, or because there is inadequate detail in either document to 
conclusively identify the match. This double counting could affect the validity of 
estimated meta-analytic effect estimates and/or falsely increase their precision. 
Fourth, authors of conference abstracts are usually constrained by the amount of 
space (number of words) available. Adherence to this constraint can come at the 
expense of an explicit and detailed description of methods used to conduct the 
clinical trial. This limits the ability of the reader of a conference abstract to 
critically assess the methods, evaluate risk of bias, and conduct a qualitative 
synthesis of the clinical trial in the context of the entire body of evidence.[87] 
Fifth, researchers and representatives of pharmaceutical companies may view 
conferences as opportunities to advertise recent results of clinical trials of drugs 
and devices to clinicians and members of professional clinical organizations. This 
can be problematic because these results might not yet or might not ever be peer 
reviewed or published, and even if they are published, research has shown that 
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pharmaceutical companies often selectively report outcome analyses and results, 
leading to outcome reporting bias.[67, 88] Sixth, searching for and obtaining 
conference abstracts is time-consuming, especially if the conference abstracts are 
not indexed by electronic databases such as MEDLINE.[89] 
 
3. Objective and specific aims of this dissertation 
 The overarching objective of this dissertation is to address important 
questions and research gaps related to selecting, specifying, measuring, analyzing, 
and reporting outcomes in clinical intervention research. To achieve this, three 
specific aims are listed below and described in detail in the following three 
chapters of this dissertation: 
• Aim 1 - Use social network analysis methods to (a) understand patterns of co-
occurrence of outcomes in systematic reviews of HIV/AIDS; and (b) identify 
outcomes that are central to the network of outcomes examined in systematic 
reviews of HIV/AIDS. 
• Aim 2 - Assess the completeness of pre-specification and comparability of 
outcomes in systematic reviews addressing four common eye conditions. 
• Aim 3 – Evaluate, using randomized controlled trials in ophthalmology, (a) 
the agreement in reported main outcome results comparing abstracts and 
their corresponding full publications; and (b) the association between author 
conflicts of interest and full publication of results presented in abstracts. 
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4. Datasets used in this dissertation 
For Aim 1, we have elected to examine systematic reviews of interventions 
to prevent and treat HIV/AIDS because of the variety of interventions and 
outcomes inherent to the field. This variety lends itself nicely to the understanding 
of patterns of co-occurrence of outcomes. We include all 140 Cochrane systematic 
reviews and systematic review protocols published by the Cochrane Review 
Group on HIV/AIDS in the Cochrane Database of Systematic Reviews as of June 
30, 2013 (Issue 6). For completed systematic reviews (n=99), we include the most 
recent version. For systematic reviews in progress (n=41), we include the protocol 
(a peer reviewed and published document outlining the planned methods 
[including outcomes to be examined]).  
 For Aim 2, we select four common eye conditions in ophthalmology 
(glaucoma, cataract, age-related macular degeneration (AMD), and diabetic 
retinopathy (DR)), because of their high disease burden across populations.[90] 
We include all 57 Cochrane systematic reviews protocols that addressed these four 
conditions and were published by the Cochrane Eyes and Vision Group (CEVG) 
in The Cochrane Database of Systematic Reviews as of June 30, 2013 (Issue 6). 
For systematic reviews for which we were able to find protocol (n=54), we include 
the protocol. For the remaining systematic reviews (n=3), we include the Methods 
section of the completed versions of the systematic review. 
For Aim 3, we include all 513 conference abstracts describing results of 
randomized controlled trials presented at the 2001-2004 Association for Research 
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in Vision and Ophthalmology (ARVO) conferences. This annual conference is the 
largest international research conference in ophthalmology in the world. Eligible 
for this study are randomized controlled trials addressing any type of intervention 
for any eye condition or in healthy volunteers.  
 
5. Significance and innovation 
All clinical intervention research involves using outcomes to examine 
whether the intervention is effective and safe. This dissertation takes a holistic 
approach to addressing important issues related to outcome use in clinical 
intervention research. We recognize that the process of using outcomes begins 
well before researchers report the results, and that it includes the steps of selection, 
specification, data collection and analysis, and reporting of the outcomes (Figure 
1-1). This dissertation addresses research gaps related to three of these steps. 
To examine outcome selection, we conduct a case study examining the 
innovative application of social network analysis methods (Aim 1). The product of 
this application is a list of central outcomes, which, used in tandem with outcomes 
that are the most frequent, can help inform the development of core outcome sets.  
Regarding the step of specifying outcomes, we adapt the outcomes 
specification framework used by ClinicalTrials.gov and propose that all clinical 
researchers, including systematic reviewers, use a five-element framework to 
specify each outcome (Aim 2). Currently, while all the five elements we propose 
are discussed in various systematic review methods guideline documents,[38-40] 
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individual elements are listed in various disparate locations in those documents. 
The idea that a five-element framework should be used for pre-specifying 
outcomes appears new to the systematic review community. 
 Finally, for reporting outcomes, we examine all conference abstracts 
describing randomized controlled trials presented at the largest research 
conference in ophthalmology in the world (ARVO) and their corresponding full 
publications (Aim 3). We evaluate the agreement in main outcome results between 
conference abstracts and full publications of the same randomized controlled trial, 
an issue important to clinicians, patients, and systematic reviewers. Also, we 
capitalize on the fact that ARVO collects conflicts of interest information from all 
authors who submit abstracts, and use that information to understand the 
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Methods to develop core outcome sets (COS), the minimum outcomes that should 
be measured in research in a topic area, vary. We applied social network analysis 
methods to understand outcome co-occurrence in HIV/AIDS systematic reviews 
(SRs), and identify outcomes central to the network of outcomes in HIV/AIDS. 
 
Methods 
We examined all Cochrane SRs of HIV/AIDS as of June 2013. We defined a tie as 
two outcomes (nodes) co-occurring in ≥2 SRs. To identify central outcomes, we 
used normalized node betweenness centrality (nNBC) (the extent to which 
connections between other outcomes in a network rely on that outcome as an 
intermediary). We conducted a subgroup analysis by HIV/AIDS intervention type 
(i.e., clinical management, biomedical prevention, behavioral prevention, and 
health services).   
 
Results 
The 140 included SRs examined 1140 outcomes, 294 of which were unique. The 
most central outcome overall was all-cause mortality (nNBC=23.9). The most 
central and most frequent outcomes differed overall and within subgroups. For 
example, adverse events (specified), was among the most central but not among 
the most frequent outcomes, overall. 
38 
Discussion 
Social network analysis methods are a novel application to identify central 
outcomes, which provides additional information about influential outcomes, 
potentially useful for developing COS.   
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INTRODUCTION 
 In clinical research, an outcome is an event or measure in study participants 
that is used to assess the effectiveness and/or safety of the intervention being 
studied.[1] What is typically thought of as the name of the outcome (e.g., 
“anxiety”, “death”), is more formally called the outcome domain.[2, 3] In this 
paper, when we say “outcome”, we are referring specifically to the outcome 
domain. Clinical trialists and systematic reviewers typically examine multiple 
outcomes in their studies, and the number of outcomes they examine varies 
widely. For example, clinical trials have been reported as examining between 1 
and 71 primary outcomes and between 0 and 122 secondary outcomes.[2] This 
variation in outcomes examined creates inconsistent outcome reporting, and is a 
threat to credible evidence synthesis because when an outcome is reported for one 
trial but not another, it is impossible to compare or synthesize results across trials, 
for example, in a meta-analysis. 
The various outcomes examined within a group of related clinical trials or 
systematic reviews constitute a network of outcomes. The network is made up of 
individual outcomes representing various categories (e.g., clinical/biological 
outcomes, behavioral outcomes). For example, a clinical trial assessing the 
efficacy of a statin for treatment of hypercholesterolemia might examine the 
clinical/biological outcomes serum cholesterol concentration and stroke. Some 
less frequently-examined, but not less relevant, outcomes might be cost-
effectiveness, patient preferences, and quality-of-life. All these outcomes might be 
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examined within clinical trials or systematic reviews, but all would not typically 
be examined within a single clinical trial or systematic review. For example, a 
study addressing mother-to-child transmission of HIV might examine a cluster of 
outcomes such as the child’s acquisition of HIV, premature delivery, neonatal 
morbidity, and neonatal mortality, outcomes that could also be examined in other 
studies on the topic. Clinical trialists and systematic reviewers alike would want 
information on relevant outcomes in that cluster to be present in all studies on the 
topic, yet this clustering may not be revealed by consensus, survey, literature 
review, or other methods of deciding on outcomes important to use across all 
studies on a topic. 
When a single study examines more than one outcome, outcomes (or 
nodes) are said to co-occur. Within a given topic area, understanding the 
underlying co-occurrence of outcomes in existing research could inform the 
development of core outcome sets. A core outcome set refers to the minimum 
outcomes that should be examined in all clinical trials addressing a specific 
condition.[4] Core outcome sets are presumed to serve two main purposes: they 
(1) facilitate decision-making by patients, clinicians, healthcare payers, and 
guideline developers by promoting consistency in the outcomes examined in the 
research informing care, and (2) reduce the potential for selective reporting of an 
outcome purely on the basis of results.[3-7] 
Social network analysis, the study of graphs as representation of 
relationships and patterns of interaction among nodes (in our case, outcomes) 
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within a network,[8] provides methodological tools to understand patterns of co-
occurrence of outcomes in a given topic area. These patterns, along with other 
information, could contribute to development of core outcome sets. To our 
knowledge, social network analysis methods have not been applied in the context 
of analysis of co-occurrence of outcomes or to identify potential outcomes for core 
outcome sets. The methods for social network analysis, with their basis in network 
theory,[9] have increasingly been applied to health-related research, however. 
Some of these applications include evaluating collaboration among 
researchers;[10-12] evaluating scholarly citation patterns in Alzheimer’s 
disease;[13] and evaluating the associations between personal relationships (e.g., 
spouses, friends) and happiness,[14] depression,[15] food choices,[16] physical 
activity,[17] alcohol consumption,[18] marijuana use,[19] and smoking.[20-22]  
Understanding the affinity (or repulsion) between certain outcomes that 
results in their co-occurrence (or not) would help identify outcomes that are 
considered central to a network of outcomes (i.e., important to the connectedness 
of other outcomes in a network) in clinical trials or systematic reviews. In a social 
network of persons, for example, centrality would describe the most influential 
person in a network, i.e., the person most important to connecting other persons in 
the network. Centrality is a way of considering which outcomes and groupings of 
outcomes have been important to researchers in the past. There are various types 
of centrality we can calculate. Betweenness centrality is a statistic that is 
calculated and assigned to each node that tells us the proportion of times, out of 
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the maximum possible, that the outcome (node) occurs in the shortest path 
between two other outcomes (or nodes).  
The Core Outcome Measures for Effectiveness Trials (COMET) Initiative 
suggests that core outcome sets for clinical trials be developed first by identifying 
potential outcomes and then establishing consensus among stakeholders.[5] 
Currently, approaches to identifying potential core outcomes vary,[23] although 
frequency of outcome occurrence in research studies provides key information. In 
the current study, using Cochrane systematic reviews, we examine whether social 
network analysis would provide any new information on the centrality of 
outcomes that have been examined in a topic area. Systematic reviews synthesize 
multiple clinical trials, and have a key role in directly informing clinical practice 
guidelines and healthcare policy. Whereas the outcomes examined in clinical trials 
are generally related to patient care and may be constrained by practical 
considerations, such as costs of outcome measurement and study power,[3] a 
different set of issues, such as the usefulness of outcomes to decision-makers, is 
likely to influence systematic reviewers. Thus, the outcomes selected by 
systematic reviewers may encompass both clinical and policy-relevant outcomes.  
 
OBJECTIVES 
We used social network analysis methods to (1) understand patterns of co-
occurrence of outcomes in systematic reviews of HIV/AIDS; and (2) identify 
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outcomes that are central to the network of outcomes examined in systematic 
reviews of HIV/AIDS. 
 
METHODS 
Choice of topic area and systematic review sample 
We selected HIV/AIDS for this case study because of the variety of 
interventions and outcomes inherent to the topic area. This variety lends itself 
nicely to the understanding of patterns of co-occurrence of outcomes. In addition, 
a recent systematic review [23] identified only one core outcome set in the area of 
HIV/AIDS, specifically for interventions addressing prevention of mother-to-child 
transmission among breastfeeding mothers.[24] 
All Cochrane systematic reviews published by the Cochrane Review Group 
on HIV/AIDS in the Cochrane Database of Systematic Reviews as of June 30, 
2013 (Issue 6) were eligible. For completed systematic reviews, we included the 
most recent version. For ongoing systematic reviews, we included the protocol (a 
peer-reviewed published document outlining the planned methods [including 
outcomes to be examined]).  
Data extraction 
We designed a data extraction form using Google Forms©. One investigator 
(IJS) extracted the following information pertaining to each systematic review: 
status (protocol only or completed systematic review), year of publication, and 
type of interventions assessed. Two investigators (IJS and CUG) independently 
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extracted, from the methods section of each systematic review, information about 
all examined outcomes, as stated in the systematic reviews. We resolved all 
discrepancies through discussion.  
Categorization of outcomes 
Two investigators (IJS and CUG) independently categorized each outcome 
into one of 14 categories: clinical/biological, behavioral, mental/social, 
antiretroviral prophylaxis/treatment, health services access/uptake, knowledge, 
testing/counseling, adverse effects, preference/satisfaction, attitudes, economic, 
quality-of-life, adherence, and miscellaneous. We developed and revised the 
categorization system during data extraction, as needed, and we completed it 
before we began the social network analysis.  
 
Social network analysis  
While the steps of social network analyses might differ based on the 
objectives of the analysis and the topic area, our social network analysis 
comprised five steps.  
 
Step 1: Defining the structure of the social network 
In the first step of our social network analysis, we defined the structure of 
the network using the concepts of nodes, ties, and isolates (explained in Box 2-1). 
We did not include all possible outcomes in our network. Instead, we defined the 
nodes as outcomes that occurred in more than one systematic review, thus 
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reducing the number of unique nodes or outcomes in the graphs we produced. We 
considered two outcomes as tied if they co-occurred in two or more systematic 
reviews. Based on this definition, we generated an adjacency matrix detailing 
whether or not each pair of outcomes was tied.[28, 29] 
 
Social network analysis – Step 2: Graphing the social network 
In step 2, we imported the adjacency matrix into UCINET 6,[30] and used 
NetDraw [31] to produce the graphs, applying principles outlined by Freeman.[32] 
Freeman recommends first using a systematic approach to position nodes on the 
graph. Using NetDraw, we employed the spring embedding layout, an approach 
that positions nodes by balancing the attraction of closer nodes with the repulsion 
of distant nodes.[32] For our analysis, this implied that outcomes that co-occurred 
were positioned closer to each other than outcomes that did not co-occur. To aid 
visualization of social network graphs, outcomes that were isolates (i.e., those that 
did not co-occur with any other outcome in two or more systematic reviews) were 
not depicted. Once nodes were positioned, we incorporated node attributes into the 
graph generated for the network, as recommended by Freeman.[32] Using color 
coding, we incorporated information about the main category we had applied to 




Social network analysis – Step 3: Calculating descriptive statistics of the social 
network 
The third step of our social network analysis was to describe the structure of 
the observed network using descriptive statistics. We employed specific statistics 
that relate to a network’s cohesion (or connectedness) and centrality (extent to 
which a network depends on intermediary nodes).  
 
Statistics related to cohesion of the network (explained in Box 2-1):  
Density - We interpreted density to be the observed co-occurrences of outcomes as 
a fraction of all possible co-occurrences. A density of zero would mean 
that no co-occurrences were observed and a density of one would mean 
that all possible co-occurrences were observed. The closer the density is to 
one, the larger is the proportion of outcome co-occurrence. 
Component – Components are subsets of nodes that are all tied directly or 
indirectly, but have no ties to nodes outside that subset [10] The existence 
of multiple components would suggest that there are silos of outcomes that 
co-occur together, but do not co-occur with outcomes outside the silo.  
 
Statistics related to centrality of the network (explained in Box 2-1):  
Conceptually, there are various kinds of centrality, such as betweenness and 
degree centrality. We chose betweenness centrality because it best describes how 
certain nodes are intermediaries, or important in connecting other nodes in a 
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network.[9. 33]. Connectivity of outcomes is an important idea because core 
outcome sets should contain outcomes that represent a range of categories of 
outcomes; outcomes that contribute to this connectivity might be of increased 
importance for core outcome sets. 
Node betweenness centrality (NBC) - In our analysis, a high NBC for a certain 
outcome would suggest that the outcome is central to the network. The 
normalized version of this statistic allows the node betweenness centrality 
of nodes to be compared across different networks.[9] We calculated 
normalized node betweenness centrality (nNBC) for each outcome in our 
overall network as well as within sub-networks by type of intervention 
(see step 5). For each network in our analysis, we considered the seven 
outcomes with the highest nNBCs to be the central outcomes of that 
network. We chose seven because Cochrane recommends including no 
more than seven main outcomes in Cochrane systematic reviews.[34] 
Using NetDraw, we depicted differences in nNBC across outcomes 
graphically by plotting each node’s size as proportional to its nNBC.  
In order to compare measures of centrality using betweenness and degree 
centrality, we also computed each outcome’s normalized node degree centrality.  
Network betweenness centralization or global betweenness centralization 
(hereafter referred to as centralization) – Unlike NBC and nNBC which 
are computed separately for each node in a network, centralization is 
computed for the network as a whole. Centralization scores range from 
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zero to one, with scores close to zero suggesting that no single node 
pervades the network and scores close to one suggesting that a single node 
pervades the network. For example, if there was only a single outcome that 
co-occurred with most other outcomes, centralization would be close to 
one. 
 
Social network analysis – Step 4: Sensitivity analysis  
In step 4 of our social network analysis, we evaluated the robustness of the 
results using sensitivity analysis. We conducted a sensitivity analysis by changing 
the definition of a tie from co-occurrence of outcomes in two or more systematic 
reviews to co-occurrence in three or more systematic reviews. We picked the 
cutoff of three or more systematic reviews because the cutoff of one or more 
systematic reviews meant including too many isolated outcomes, and the cutoff of 
four or more systematic reviews meant including too few outcomes to 
meaningfully visualize patterns of co-occurrence.  
 
Social network analysis – Step 5: Subgroup analysis 
Step 5 of a social network analysis was to examine the results within sub-
networks (or subgroups) of the entire network. We conducted a subgroup analysis 
using the Cochrane Review Group on HIV/AIDS’s system for classifying its 
systematic reviews by type of intervention: (a) therapeutics, prognostics, and 
diagnostics (“clinical management”); (b) biomedical prevention (“biomedical 
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prevention”); (c) behavioral, social, and policy prevention (“behavioral 
prevention”); and (d) organization and financing of health services and care 
(“health services”). 
To evaluate whether social network analysis would provide more 
information than a simple frequency analysis of outcomes examined in our sample 
of systematic reviews, we compared the seven most central outcomes (i.e., those 
with the highest nNBCs) with the seven most frequent outcomes (i.e., those 
examined in the highest percentage of systematic reviews) overall and for each 
sub-network. 
We analyzed descriptive statistics using STATA© version 12 (College 
Station, TX). We graphed and analyzed all networks using the UCINET 6 [30] and 




Characteristics of systematic reviews and outcomes 
We identified 140 eligible systematic reviews (Table 2-1), all published in 
the year 2008 or later, of which 99 (70.7%) were completed. Almost half of the 
systematic reviews belonged to the intervention subgroup of clinical management 
(69/140; 49.3%). Box 2-2 lists examples of interventions assessed by subgroup. 
The 140 systematic reviews examined a median of seven outcomes each 
(interquartile range [IQR] 4-11, range 1-30). Across the 140 systematic reviews, 
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overall, there were 1140 outcomes examined, 294 of which were unique. The most 
frequently-examined outcomes were all-cause mortality (68/140; 48.6%), 
cost/cost-effectiveness for patients (50/140; 35.7%), and CD4 count (42/140; 
30.0%) (Table 2-2). Also known as T-helper cells, CD4 refers to the cluster of 
differentiation 4 positive T-cells. 
 
Categorization of outcomes 
Figure 2-1 displays the classification of the 294 outcomes into the 14 
categories we defined. Most outcomes fell into one of three categories: 
clinical/biological (160/294; 54.4%), behavioral (51/294; 17.4%), and 
mental/social (17/294; 5.8%). Almost half of the outcomes (138/294; 47%) 
appeared in only one review.  
 
Social network analysis – Steps 1 and 2: Defining the structure and graphing the 
social network  
After defining a tie as outcome co-occurrence in two or more systematic 
reviews (step 1), we graphed the social network (Figure 2-2). This graph served as 
exploratory analysis, displaying 156 of the 294 outcomes. The remaining 138 
outcomes were isolates, and therefore were not displayed. Two main clusters of 
outcomes were evident in the graph (clinical/biological outcomes and behavioral 
outcomes), though the clustering was not mutually exclusive. For example, some 
clinical/biological outcomes (e.g., incidence of sexually-transmitted infections 
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[code G9], incidence of HIV infection [code G11]) clustered with behavioral 
outcomes. A few outcomes (e.g., cost/cost-effectiveness for patients [code L2] and 
adverse events [unspecified] [code A2]) appeared to bridge the two main clusters. 
 
Social network analysis – Step 3: Calculating descriptive statistics of the social 
network 
After exploratory analysis, we re-sized each outcome on the social network 
graph to be proportional to its nNBC (Figure 2-3). Overall, the most central 
outcomes were all-cause mortality (code G25), cost/cost-effectiveness for patients 
(code L2), and adverse events (unspecified) (code A2) (Table 2-2).  
Because the centralization of the network is closer to zero than to one (0.27), it did 
not provide strong evidence for the domination of the social network from all 140 
systematic reviews by the most central outcome (i.e., all-cause mortality, 
nNBC=23.9). The network appeared dense, and there was only one component; 
nevertheless, the overall cohesion of the network was low (density=0.09). This can 
be explained by the fact that the outcomes clustered and that only a few ties 
between outcomes bridged those clusters (i.e., the connections, and thus density, 
between the clusters was low). Further, most outcomes were examined in only a 
few systematic reviews each (median=2, IQR=1-3), limiting the overall co-




Social network analysis – Step 4: Sensitivity analysis 
When we changed the definition of a tie from co-occurrence of outcomes in 
two or more systematic reviews to co-occurrence in three or more systematic 
reviews, the number of tied outcomes dropped from 156 to 96, but the density 
changed negligibly (from 0.09 to 0.10) and the centralization remained unchanged 
(0.27). Six of the top seven central outcomes were the same, while the seventh 
outcome ‘unprotected sex’ was replaced by adherence. 
 
Social network analysis – Step 5: Subgroup analysis  
We identified the seven most central and the seven most frequent outcomes 
across all 140 systematic reviews and by intervention-defined subgroups (Table 2-
2 and Figure 2-4, subgroups sorted by increasing density). The lists of outcomes 
differed across sub-networks. When we compared the findings of the social 
network analysis with the frequency analysis of outcomes in the 140 systematic 
reviews, we noted that certain outcomes would be missed if one considered only 
frequency or only centrality. For example, adverse events (specified), a patient-
important outcome, was one of the most central outcomes in the overall network 
(nNBC=14.8), but not one of the most frequent (17/140 systematic reviews; 
12.1%). Similarly, the same outcome was the most central outcome in the 
biomedical prevention subgroup (nNBC=33.3), but not one of the most frequent 
(2/20 systematic reviews; 10.0%). This suggests that while this outcome was not 
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very frequently used in the systematic reviews, it was important to connecting 
other outcomes in the networks.  
When we compared each network’s seven most central outcomes using 
betweenness and degree centrality, we noted that the outcomes so identified were 
generally similar. For example, in the health services subgroup, the seven most 
central outcomes identified using betweenness and degree centrality were the 
same, except that the sixth (cost/cost-effectiveness for patients) and the seventh  
(hospitalization) most central outcomes identified using betweenness centrality 
swapped positions in the list of the seven most central outcomes identified using 
degree centrality (data not shown). 
The nNBC statistics revealed that the evidence supporting the most central 
outcomes in the sub-networks of clinical management and biomedical prevention 
was stronger than the evidence supporting the most central outcomes in the other 
two sub-networks. This observation is a consequence of how centralization is 
computed, i.e., networks with large differences in nNBC between their two most 
central outcomes have high centralization scores. For example, in the most 
centralized sub-network, clinical management (centralization=0.37, Table 2-3), the 
most central outcome (all-cause mortality) had considerably higher nNBC than 
that of the next most central outcome (38.2 vs. 13.0, Table 2-2). On the other 
hand, in the least centralized sub-network, health services (centralization=0.12, 
Table 2-3), the difference in nNBC between the two most central outcomes was 
not as great (14.1 vs. 8.7). While all-cause mortality was the most central outcome 
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in both these sub-networks, it was more central to the clinical management sub-
network than the health services sub-network (nNBC 38.2 vs. 14.1, respectively, 
Table 2-2). The comparison of nNBCs for the same outcome in different networks 
is valid because of the normalized nature of this statistic. 
The inverse relationship between density and centralization for the sub-
networks (Table 2-3) suggests that the more dense (or cohesive) sub-networks 
were less centralized around their most central outcome. All sub-networks 
included one component each, except for the biomedical prevention sub-network 
(Figure 2-4b) which contained two components (one of which is tiny). 
 
DISCUSSION 
Choice of outcomes is a critical step in study design of both clinical trials 
and systematic reviews, and yet, current approaches to inform that choice vary. 
Inconsistent use of outcomes leads to systematic reviewers being unable to 
compare results across studies or synthesize results in a meta-analysis, threatening 
the credibility and potential impact of evidence synthesis. In this case study, we 
draw from the toolbox of social network analysis and apply these methods to 
identify systematically central outcomes (important to the connectedness of other 
outcomes in the network) in systematic reviews of HIV/AIDS. Examining all 140 
Cochrane systematic reviews published by the Cochrane Review Group on 
HIV/AIDS, we identified 294 unique outcomes overall, across four pre-specified 
intervention subgroups defined by Cochrane. Before beginning our social network 
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analysis, we grouped or categorized outcomes to manage the large number of 
outcomes and to examine their approximate topic coverage. Whereas other 
researchers might reasonably differ in how they would categorize these outcomes, 
the general overlap between our categorization system and the spring embedding-
based clustering of outcomes in the social network graphs provided a posteriori 
support for our categorization system. Moreover, our categories incorporate, either 
as main categories or subcategories, each of the 15 categories used during a recent 
survey of outcome reporting in Cochrane systematic reviews.[35] However, future 
investigators might use community detection algorithms [36] to formally evaluate 
the extent of overlap between pre-defined categories of outcomes and social 
network analysis-identified communities of outcomes.  
We identified the seven most central outcomes for HIV/AIDS interventions 
overall as well as separately for each intervention sub-network, considering 
outcomes with the highest values of nNBC to be central to a network. For two 
intervention sub-networks (clinical management and biomedical prevention) in 
particular, we observed some evidence supporting pervasion of the networks by 
their single most central outcomes. While the nNBC statistic identifies the most 
central outcomes in a network, the difference in nNBC between the most and 
second most central outcomes allow7s assessment of the extent to which the most 
central outcome pervades the network. High centralization and large differences in 
nNBC imply pervasion by that outcome. Future research should evaluate whether 
a minimum nNBC cutoff can be used to determine whether or not a given outcome 
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is central to a network. Furthermore, it is unclear whether seven outcomes is the 
optimal number for examining centrality. In future testing of this method, 
researchers may want to examine whether there is additional gain from comparing, 
for example, a larger number of outcomes. 
 
What is gained by examining centrality? 
To ensure that important outcomes are not missed, we suggest that those 
developing core outcome sets begin by considering both frequent and central 
outcomes. Social network analysis capitalizes on the underlying affinity and 
repulsion between outcomes, thus identifying co-occurring central outcomes (as 
opposed to frequent outcomes) in existing research. Central outcomes, the most 
important outcomes in a network, are readily visualized on social network graphs 
and captured statistically using the nNBC statistic. When we compared the most 
central with the most frequent outcomes overall or in a sub-network, we observed 
some differences. Although there was some overlap, there was additional 
information conveyed by the social network analysis that took co-occurrence into 
account. For example, the list of most frequent outcomes, overall, excludes the 
outcome of adverse events (specified), a patient-important outcome that we 
considered central using social network analysis. So, if frequency were used as the 
sole determinant for identifying outcomes for a core outcome set, adverse events 
(specified) would have been missed. Similarly, in the sub-networks, all-cause 
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mortality, viral load, and symptom resolution are examples of outcomes that 
would have been missed if frequency were solely used.  
When comparing the two lists of frequent and central outcomes, we 
observed somewhat striking differences in the more centralized sub-networks (i.e., 
clinical management [centralization=0.37] and biomedical prevention 
[centralization=0.29]) compared with the less centralized sub-networks. For 
example, in the biomedical prevention sub-network, three of the seven most 
central outcomes were not among the seven most frequent, and vice versa. On the 
other hand, in the health services sub-network (the least centralized sub-network), 
there was only one exclusive outcome in each list. One interpretation of this 
observation is that the social network analysis approach might be more valuable in 
more centralized networks compared with less centralized networks (i.e., networks 
in which the overlap between central and frequent outcomes is greater). Before 
considering this interpretation further, other disease areas should be examined to 
see whether this finding can be more generally applied.  
There are various types of centrality defined in social network analysis. We 
chose to use betweenness as a measure of centrality because it identifies outcomes 
as central if they are important to the connectedness of the network. Degree 
centrality measures the number of direct connections that each node has.[8] 
Eigenvector centrality is the measure of the influence of a node, or outcome, in a 
network.[8] Closeness centrality is related to the shortest distance between pairs of 
nodes.[8] While the latter three types of centrality capture important 
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characteristics of outcomes in a network, betweenness centrality captures a 
concept fundamental to developing core outcome sets, the connectedness of the 
entire network and how the outcomes in a network relate to one another. Future 
investigators may wish to explore other measures of centrality. In our data, the 
most central outcomes identified using betweenness and degree centrality were 
generally similar. 
 
Developing core outcome sets using social network analysis 
It can reasonably be assumed that the existence and promotion of core 
outcome sets would enhance the comparability of outcomes across research in a 
given topic area.[4] Although core outcome sets represent an attempt at 
standardization of outcomes examined and reported, they are developed using a 
variety of methods, sometimes arbitrarily. Some of the methods used include the 
Delphi technique, semi-structured group discussions (e.g., workshops), 
unstructured group discussions, literature/systematic reviews, and surveys.[23] 
The use of formal processes has been recommended by the COMET Initiative,[23] 
the Patient-Reported Outcomes Measurement Information System (PROMIS),[37] 
and the Outcome Measures in Rheumatology (OMERACT) Initiative.[38] 
While it is too early to decide on an optimal method for develop core 
outcome sets, we believe social network analysis can contribute a perspective that 
adds to traditional frequency, consensus, and survey methods. Central outcomes 
should not automatically be considered as core outcomes. Our study does not test 
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various methods for developing core outcome sets; rather, we explore a method 
(social network analysis) that could contribute by identifying potential outcomes 
(central outcomes) for core outcome sets in a single topic area, HIV/AIDS. 
Because we have demonstrated that some central outcomes would be missed if one 
were only to consider the most frequent outcomes, for the topic area of 
HIV/AIDS, we suggest incorporation of this perspective would add value to the 
process of core outcome set development. Once the list of potential outcomes is 
obtained from both frequent and central outcomes, assuming involvement of all 
stakeholders, the next step should be to develop core outcome sets. A critical 
component of core outcome set development is the assurance that all stakeholders, 
including patients, have a voice in the process. 
Because our social network analysis demonstrated different central 
outcomes across the intervention sub-networks, we believe that tailoring core 
outcome sets by intervention approach is beneficial. Even in the instance where 
the most central outcome for two sub-networks was the same (i.e., all-cause 
mortality in the sub-networks of clinical management and health services), this 
outcome was more central to the former sub-network than the latter (nNBC 38.2 
vs. 14.1). This suggests stronger evidence for including all-cause mortality in a 
core outcome set for clinical management than for health services in HIV/AIDS. 
Another aspect related to the sub-networks in our study that bears 
discussion is the fact that the outcomes in the sub-networks were obtained from 
Cochrane-defined subgroups of HIV/AIDS reviews. In most subgroups, there were 
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both different types of interventions as well as different types of populations. In 
the overall network, the different types of interventions included both preventive 
and therapeutic interventions. Those developing core outcome sets in a topic area 
should consider whether separate core outcome sets are warranted by type of 
intervention, type of population, or both. The networks of outcomes would need to 
be constructed accordingly. The networks we constructed reflect the Cochrane 
Review Group on HIV/AIDS’s classification of its systematic reviews. 
 
Developing core outcome sets starting with systematic reviews 
Systematic reviews are an excellent starting point for identifying central 
outcomes for core outcome sets. Existing systematic reviews in a topic area, when 
considered together, appraise a large portion of the evidence, much of it from 
clinical trials. Although it bears further investigation, deriving central outcomes 
from systematic reviews is potentially useful for designing clinical trials relevant 
for systematic reviews and decision-making. Another argument for using 
systematic reviews to help develop a core outcome set, is that it is recommended 
that systematic reviews (e.g., Cochrane systematic reviews [34]) include patient 
representatives in the process. If followed, this recommendation allows for broader 
input on outcome inclusion. Further, systematic reviews of intervention 
effectiveness pre-specify outcomes and indicate where these outcomes are missing 
from clinical trial reports.[3, 39, 40] For example, the choice of outcomes in a 
clinical trial may be related to what data can be gathered easily (i.e., interim 
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outcomes), and may not always address the questions that need to be answered. 
An example of this is the focus of glaucoma clinical trials on intraocular pressure 
(a risk factor for glaucoma) instead of visual field, the patient-important outcome 
that influence’s visual function.[41]  
Cochrane systematic reviews use fairly standardized processes within 
review groups. For approximately 36% of Cochrane review groups, the review 
group’s editorial team makes decisions about outcome selection and the relative 
importance of outcomes for all reviews under the group’s purview.[42] In the area 
of HIV/AIDS, however, Cochrane systematic review authors propose a list of 
outcomes to be examined in the systematic review, with additions and deletions 
suggested by the Review Group’s editorial team and peer reviewers, which often 
include patients and other stakeholders. As far as we know, there is only one core 
outcome set related to the area of HIV/AIDS, and it is specifically related to 
prevention of mother-to-child transmission of HIV among breastfeeding 
mothers.[24] Thus, the central outcomes we identified likely reflect the 
preferences of the larger community of Cochrane systematic review authors in 
HIV/AIDS, rather than just those of the Review Group. However, in smaller topic 
areas where the same authors might contribute to a large proportion of the 
systematic reviews, it is possible that the central outcomes identified might be 
greatly influenced by those authors’ preferences, rather than the larger community 
of stakeholders in that topic area.  
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It is possible, however, that systematic reviews are not the best source 
materials for developing a core outcome set. Systematic reviews have been shown 
to sometimes miss important outcomes reported in clinical trials.[40]  Therefore, 
the number of outcomes examined in clinical trials included in the systematic 
reviews we examined might be greater than the number of outcomes examined in 
the systematic reviews alone. Although Cochrane recommends that systematic 
reviewers examine outcomes without considering clinical trial outcomes,[34] we 
believe that future studies should examine the central outcomes of networks 
developed using the two different sources of information (clinical trials and 
systematic reviews). The amount of overlap between the two networks would help 
address whether those developing core outcome sets should focus on outcomes 
examined in systematic reviews, clinical trials, or both. 
 
Conclusions 
We believe that the novel application of social network analysis methods to 
identify outcomes that are central to network of outcomes in HIV/AIDS using 
Cochrane systematic reviews provides important information needed for the 
development of core outcome sets. Social network analysis can uncover co-
occurrence patterns of HIV/AIDS outcomes likely not discernable using simple 
frequency counts and other currently used methods. We identified seven of the 
most central outcomes across all interventions as well as for intervention sub-
networks. While there was some overlap, the outcomes identified using methods 
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to identify co-occurrence and centrality were different from those identified using 
frequency of occurrence alone. Although our results are preliminary, the methods 
appear feasible and deserve further study.  
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Box 2-1 – Explanation for relevant social network analysis concepts and statistics  
Concept/Statistic Explanation 
Concepts related to structure 
 
Node Each individual actor in a network. 
 
Tie or Edge 
 
Underlying connection between individual nodes, represented 




A node that is not tied to any other node in a network. 




The number of ties in a network as a fraction of the total 





A subset of nodes that are all tied directly or indirectly, but 
have no ties to nodes outside that subset.[10] 




The shortest path linking a given pair of nodes in a network via 
intermediate nodes.[8] Note that there may be multiple 




This statistic is calculated for each node in the network. First, 
consider all geodesic distances connecting nodes ‘j’ and ‘k’ in 
an entire network (gjk). Next, consider the proportion of those 
distances that pass through a certain other node ‘i’ (gjk(i)). For 
node ‘i’, its NBC refers to that proportion, summed across all 
pairs of nodes in the network.[9, 33] NBC for node ‘i’ is 




where:      gjk =  number of geodesics between nodes ‘j’ and ‘k’  
               gjk(i) = number of geodesics between nodes ‘j’ and ‘k’ 
that pass through node ‘i’ 
 
Therefore, for a given node, its NBC reflects the extent to 
which connections between other nodes in the network rely on 



















This statistic is also calculated for each node in the network. 
The nNBC is a normalized version of the node betweenness 
centrality, and is calculated by dividing the node betweenness 










This statistic applies to the network as a whole. Centralization 
measures the extent to which the network is centered around 
the most central node (i.e., the node with the highest NBC).[9, 





where:      NBC* =  largest individual NBC in the network  
                 NBCi  = NBC of node i 
 
Therefore, the centralization simply is the sum of the 
difference in NBC between the most central node in the 
network and each of the other nodes, normalized by the 
maximum possible sum of the differences had the network 






















Box 2-2 – Examples of interventions addressed in included Cochrane systematic 
reviews, by type of intervention  
Clinical management 
• Abacavir-based triple nucleoside regimens for maintenance therapy in patients 
with HIV 
• Stavudine, lamivudine and nevirapine combination therapy for treatment of 
HIV infection and AIDS in adults 
• Effectiveness of antiretroviral therapy in HIV-infected children under 2 years of 
age 
• Herbal medicines for treating HIV infection and AIDS 
• Topical treatments for HIV-related oral ulcers 
 
Biomedical prevention 
• Nonoxynol-9 for preventing vaginal acquisition of HIV infection by women 
from men 
• Antiretroviral post-exposure prophylaxis (PEP) for occupational HIV exposure 
• Interventions for preventing late postnatal mother-to-child transmission of HIV 
• Sperm washing to prevent HIV transmission from HIV-infected men but 
allowing conception in sero-discordant couples 
 
Behavioral prevention 
• Behavioral interventions to promote condom use among women living with 
HIV 
• Behavioral interventions for preventing HIV infection in homeless or unstably-
housed adults 
• Behavioral interventions to reduce risk for sexual transmission of HIV among 
men who have sex with men 
• Interventions for reduction of stigma in people with HIV/AIDS 
• Male circumcision for prevention of homosexual acquisition of HIV in men 
 
Health services 
• Home-based care for reducing morbidity and mortality in people infected with 
HIV/AIDS 
• Integration of HIV/AIDS services with maternal, neonatal and child health, 
nutrition, and family planning services 
• Setting and organization of care for persons living with HIV/AIDS 
• Interventions to improve adherence to antiretroviral therapy in children with 
HIV infection 
• Mobile phone text messaging for promoting adherence to antiretroviral therapy 






Table 2-1 – Characteristics of 140 Cochrane systematic reviews examined 




Year of publication 
  
 2008 6   (4.3)  
 2009 34 (24.3) 
 2010 18 (12.9) 
 2011 35 (25.0) 
 2012 31 (22.1) 




 Protocol* 41 (29.3) 
 Completed review 99 (70.7) 
 
Type of intervention assessed 
  
 Clinical management 69 (49.3) 
 Biomedical prevention 20 (14.3) 
 Behavioral prevention 28 (20.0) 
 Health services 23 (16.4) 
*A protocol is a peer-reviewed published document outlining the planned methods of a 
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Choice of outcomes is critical for clinical trialists and systematic reviewers. It is 
currently unclear how systematic reviewers choose and pre-specify outcomes for 
systematic reviews. Our objective was to assess the completeness of pre-
specification and comparability of outcomes in all Cochrane reviews addressing 
four common eye conditions. 
Methods 
We examined protocols for all Cochrane reviews as of June 2013 that addressed 
glaucoma, cataract, age-related macular degeneration (AMD), and diabetic 
retinopathy (DR). We assessed completeness and comparability for each outcome 
that was named in ≥25% of protocols on those topics. We defined a completely-
specified outcome as including information about five elements: domain, specific 
measurement, specific metric, method of aggregation, and time-points. For each 
domain, we assessed comparability in how individual elements were specified 
across protocols.  
Results 
We identified 57 protocols addressing glaucoma (22), cataract (16), AMD (15), 
and DR (4). We assessed completeness and comparability for five outcome 
domains: quality-of-life, visual acuity, intraocular pressure, disease progression, 
and contrast sensitivity. Overall, these five outcome domains appeared 145 times 
(instances). Only 15/145 instances (10.3%) were completely specified (all five 
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elements) (median=three elements per outcome). Primary outcomes were more 
completely specified than non-primary (median=four versus two elements). 
Quality-of-life was least completely specified (median=one element). Due to 
largely incomplete outcome pre-specification, conclusive assessment of 
comparability in outcome usage across the various protocols per condition was not 
possible. 
Discussion 
Outcome pre-specification was largely incomplete; we encourage systematic 
reviewers to consider all five elements. This will indicate the importance of 
complete specification to clinical trialists, on whose work systematic reviewers 
depend, and will indirectly encourage comparable outcome choice to reviewers 
undertaking related research questions. Complete pre-specification could improve 
efficiency and reduce bias in data abstraction and analysis during a systematic 
review. Ultimately, more completely specified and comparable outcomes could 




In clinical trials, an outcome is an event or measure in study participants 
that is used to assess the effectiveness and/or safety of the intervention being 
studied.[1] Choosing relevant outcomes is a critical early step in the design of 
clinical trials and systematic reviews for a number of reasons.[2] In clinical trials, 
expected effect sizes on critical outcomes are used to determine sample size.[3] In 
addition, there is general agreement that by pre-specifying the primary and 
secondary outcomes and limiting the number of statistical analyses, clinical 
trialists reduce the likelihood of Type I error (i.e., finding a statistically significant 
treatment effect just by chance, in the absence of a true treatment effect) and 
outcome reporting bias (i.e., selectively reporting outcomes based on the strength 
and/or direction of the findings). Although satisfactory solutions have not yet been 
developed, there is growing recognition that these issues also apply to systematic 
reviews.[4, 5] Indeed, the Cochrane Collaboration recommends that systematic 
reviewers limit the number of and pre-specify all outcomes for their systematic 
review.[6, 7]  
The process of conducting a systematic review of intervention effectiveness 
begins with formulating a research question, and then, finding and synthesizing 
the evidence from studies that address the question. In formulating the question, 
the systematic reviewer defines the population, intervention, comparison, and 
outcomes (PICO) to be examined. Studies that address the review question, 
typically clinical trials, should be broadly similar on the population, intervention 
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and comparison groups, but frequently report different outcomes from those 
chosen by the systematic reviewer. Clinical trialists typically measure numerous 
outcomes, sometimes in the hundreds.[8] It is likely that these outcomes are 
different from those chosen by the systematic reviewer; overlap of the chosen 
outcomes can vary from none to complete (Figure 3-1). In many cases, the 
primary outcome of interest to the systematic reviewers may not have been an 
outcome of interest to the clinical trialists,[9] or may not be reported clearly or 
consistently in the clinical trial reports or associated documents.[10] Systematic 
reviewers thus face an important decision: should they choose outcomes to be 
examined based on what they believe to be important outcomes (“systematic 
review author judgment”) or based on what they know is reported in the relevant 
clinical trials (“clinical trialist judgment”)? 
How systematic reviewers choose outcomes and pre-specify them in 
systematic review protocols is currently unclear. One view is that, unlike clinical 
trialists, systematic reviewers should not base outcome choice on sample 
size/power calculations and Type I error rates. Instead, the objective of medical 
research should be to draw conclusions based on all sources of available 
evidence.[11] Systematic reviews, which are often used to inform clinical practice 
guidelines and policy, could and even should include all the outcomes that 
patients, clinicians, and policy-makers need to know about. Systematic reviews 
also allow elucidation of existing research gaps in a given field,[12] for example, 
when outcomes are not examined in trials and should be. 
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In our view, regardless of who chooses the outcomes to be assessed in a 
systematic review and how those outcomes are chosen, all outcomes need to be 
specified completely and clearly if they are to be of use to decision-makers.  
The objective of our study was to assess the completeness of pre-
specification and comparability of outcomes in all Cochrane reviews addressing 
four common eye conditions. Our purpose is not to hold systematic review 
protocols to a standard that may not have been described at the time they were 
published, rather it is to initiate a discussion on important questions for systematic 
reviewers: how should systematic reviewers choose outcomes to address in the 
review; how should these outcomes be reported (i.e., which elements are necessary 
for complete reporting) by systematic reviewers; and if outcomes are pre-specified 
in systematic review protocols, should these protocols be formally updated with 
amendments to reflect changing outcome specification? 
  
METHODS 
Review protocols examined 
The Cochrane Collaboration publishes and archives all its systematic 
review protocols, completed reviews, and updates in The Cochrane Database of 
Systematic Reviews. Protocols for systematic reviews, hereafter referred to as 
‘protocols’, were eligible for our study if they were published by the Cochrane 
Eyes and Vision Group (CEVG) in The Cochrane Database of Systematic Reviews 
in or before June 2013 (Issue 6), and if they addressed any of the following four 
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eye conditions: glaucoma, age-related macular degeneration (AMD), cataract, and 
diabetic retinopathy (DR). We selected these four conditions because of their high 
disease burden across populations and the range of interventions addressing 
them.[13] For each eligible review, we identified the oldest available protocol and, 
when no protocol could be found for a review, we contacted CEVG editors and 
review authors via email to ask whether they had a copy. When these efforts were 
not successful, we used the most recent version of the completed review in place 
of the protocol. 
 
Five elements of a completely specified outcome 
We used an outcome definition that includes five elements: (1) the domain 
or outcome title (e.g., visual acuity); (2) the specific measurement or 
technique/instrument used to make the measurement (e.g., Snellen chart); (3) the 
specific metric or format of the outcome data from each participant that will be 
used for analysis (e.g., value at a time-point, change from baseline); (4) the 
method of aggregation or how data from each group will be summarized (e.g., 
mean, percent/proportion); and (5) the time-points that will be used for analysis 
(e.g., 3 months) (Figure 3-2). Whereas Zarin et al. specify these same elements,[8] 





Selecting outcome domains for data extraction  
Before beginning data extraction, one investigator (IS) identified all 
outcome domains in the Methods sections of included protocols. We then selected 
for data extraction those outcome domains appearing in at least 25% of eligible 
protocols. Then, for those eligible protocols with published completed reviews, we 
compared the Methods section of the protocol with the Methods section of the 
most recent version of the corresponding completed review, noting any differences 
in the specified outcome domains. We did this step to evaluate whether focusing 
on the protocols, some of which were published a while ago, would mean that we 
were assessing a different set of outcome domains than those currently being 
evaluated by the review authors.  
 
Data extraction 
We designed, tested, and finalized a data extraction form using Google 
Forms©. Two investigators (IS and XW) extracted data independently and 
resolved discrepancies through consensus or discussion with a third author (TL). 
We extracted data about the eye condition and year of publication of each 
protocol. We extracted from the Methods section the following data pertaining to 
each eligible outcome: type of outcome (primary, non-primary, or unclear [if not 
specified]) and each of the five outcome elements described earlier. For element 2, 
we extracted all specific measurements that were specified, or classified the 
specific measurement as unclear (if not specified). We classified element 3 
93 
(specific metric) into one or more of the following categories: (i) value at a time-
point, (ii) time-to-event, (iii) change from baseline, and (iv) unclear (if not 
specified). We classified element 4 (method of aggregation) into one or more of 
the following categories: (i) mean, (ii) median, (iii) percent/proportion, (iv) 
absolute number, and (v) unclear (if not specified). For element 5, we extracted all 




We assessed the extent of completeness using the number of elements 
specified out of five possible, and considered an outcome specified in the Methods 
section as “complete” if all five elements were specified. For each outcome, we 
calculated median, interquartile range (IQR), and proportion of outcome elements 
specified. We performed Kruskal-Wallis tests for nonparametric comparisons of 
medians and distributions of extent of completeness by condition addressed, year 
of protocol publication, type of outcome, and outcome domain.  
We assessed the frequency and comparability of outcome elements (i.e., 
similarity of categories for each element) for elements 3 and 4 across protocols 
addressing each of the four eye conditions. Protocols could specify more than one 
category for a given element. Comparability was therefore assessed as the 
distribution of those categories across protocols. As an example, if one protocol 
specified visual acuity at a time-point as well as change in visual acuity from 
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baseline, we counted both categories for specific metric (element 3). In another 
example, protocols addressing cataract and assessing the outcome of visual acuity 
were considered to be comparable in method of aggregation (element 4) if they all 
specified mean or all specified median or both. However, they would not be 
comparable in element 4 if some specified mean and others specified median. 
Statistical significance was defined at the 5% level. All data were analyzed 
using STATA© version 12 (College Station, TX).  
 
RESULTS 
Characteristics of protocols examined 
Our search identified 57 eligible systematic reviews (Table 3-1). We were 
able to find protocols for 54 reviews (94.7%), and used the Methods section of 
completed reviews for the remaining three (5.3%). An updated protocol was 
published for one of the 54 protocols. Glaucoma was the most frequently 
addressed condition (22 protocols), followed by cataract (16 protocols), AMD (15 
protocols), and DR (4 protocols). Approximately half of the protocols (29/57; 
50.9%) were published between 2006 and 2010. Thirty-four protocols were 
associated with a completed review, the most recent version of which was 





Outcome domains used in protocols  
We examined five outcome domains named in at least 25% of the eligible 
protocols (Table 3-2): quality-of-life (47/57 protocols; 82.5%), visual acuity 
(47/57; 82.5%), intraocular pressure (21/57; 36.8%), disease progression (15/57; 
26.3%), and contrast sensitivity (15/57; 26.3%). One protocol did not name any of 
these five outcome domains. For most completed systematic reviews (30/34; 
88.2%), these five outcome domains were similar to what was named in their 
corresponding protocols. Compared to their protocols, two completed systematic 
reviews dropped quality-of-life while one completed review added it. One 
completed systematic review dropped contrast sensitivity.  
 
Completeness of outcome pre-specification 
 Across the 57 protocols, the five most frequent outcome domains appeared 
145 times (‘instances’); however, only 15/145 instances (10.3%) involved 
complete pre-specification (i.e., where all five elements of the outcome were 
specified). Overall, a median of three (IQR 2-4) elements were specified per 
outcome (Table 3-3). Extent of completeness was not statistically significantly 
different by condition. Completeness of outcome specification may be better in 
protocols published later compared to earlier, (median of three [IQR 2-4] elements 
specified in 2006-2010 versus one [IQR 1-3] in 2000 or earlier), although the 
difference was not statistically significant (p=0.1635).  
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Fifty-four of 57 protocols (94.7%) specified at least one primary outcome. 
Among the five outcome domains evaluated in our study, at least one was a 
primary outcome in 48/57 (84.2%) protocols. Extent of completeness appeared to 
differ by outcome type, with primary outcomes being most completely specified 
and outcomes with type unclear being least completely specified (median four 
versus one respectively, p=0.0001). Intraocular pressure was the most completely 
specified outcome in our sample, with a median of four (IQR 3-4) elements 
specified (Table 3-2). Quality-of-life was least completely specified, with a 
median of one (IQR 1-2) element specified. The patterns of completeness of 
individual elements were similar across outcomes (Figure 3-3). Method of 
aggregation was specified least often, while domain and time-points were 
specified more often than other elements. The completeness of individual elements 
for the quality-of-life outcome was less than for other outcomes, overall. Although 
intraocular pressure was the most completely specified outcome, only 24% of 
protocols assessing it specified the specific measurement. Patterns of completeness 
of individual outcome elements also appeared to be similar across conditions, 
except for outcomes in DR protocols, where there were only four protocols and so 
the percentages are unlikely to be reliable (Figure 3-4). 
Table 3-4 provides some examples of incomplete specification of outcomes 




Comparability of outcome elements 
Table 3-5 shows the distribution of specific metrics (element 3) and 
methods of aggregation (element 4) across instances of usage of outcome domain, 
by condition. The specific metric was unclear for large proportions of individual 
instances (often as high as 100% for the 16 instances of usage of quality-of-life in 
protocols addressing glaucoma and for the four instances of usage of contrast 
sensitivity in protocols addressing cataract). For instances where the specific 
metric was specified, the most frequent specific metrics were ‘value at a time-
point’ and ‘change from baseline’.  
The method of aggregation was unclear for large proportions of individual 
instances (often as high as 100% for the 16 instances of usage of quality-of-life in 
protocols addressing glaucoma and for the four instances of usage of visual acuity 
in protocols addressing DR). For instances where the method of aggregation was 




Summary of main findings 
We have shown that, if outcome pre-specification in systematic review 
protocols is judged using recommended standards for clinical trials, then it is 
largely incomplete. Although completeness appears to have improved somewhat 
over time, on average, only three of five standard elements of an outcome were 
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pre-specified. Due to largely incomplete outcome pre-specification, a conclusive 
assessment of comparability in outcome elements across the various protocols per 
condition was not possible. However, we observed variation in specific metrics 
and methods of aggregation. 
 
Completeness of outcome pre-specification 
There are some reasons that might explain why outcomes were not 
completely specified in our study of systematic review protocols. First, although 
we believe complete specification of all five elements is necessary for a number of 
reasons, the idea is new to the systematic review community. This is demonstrated 
by the fact that the Cochrane Handbook states only that the name of the outcome 
(equivalent to domain [element 1]), type of scale (equivalent to specific 
measurement [element 2]), and timing of measurement (equivalent to time-points 
[element 5]) must be pre-specified6; and there is no explicit mention of pre-
specification of specific metric (element 3) or method of aggregation (element 4). 
Indeed, elements 1 and 5 were the most often-specified elements in our sample of 
protocols, though element 2 was frequently not specified (70% of the time) 
(Figure 3-3).  
Another possible explanation for incomplete pre-specification of outcomes 
is that choice of outcomes could be influenced by the findings of (and outcomes 
examined in) the clinical trials that would be included in the review. We did not 
assess the outcomes examined at the level of the clinical trials to determine the 
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likelihood that this occurred, but suggest that doing so may contribute to a better 
understanding of how review outcomes are chosen. Are they chosen because 
systematic reviewers consider them the most important outcomes to examine, 
because they are the outcomes that have been examined in clinical trials, or both? 
If the review outcomes were chosen purely because they were the outcomes that 
have been reported in clinical trials, this is troubling because of the possibility of 
“meta-bias”. We know, for example, that outcomes reported in clinical trials could 
have been selectively reported because of desirable or undesirable findings.[14, 
15] By pre-specifying in the protocol the outcomes to be examined in the review, 
systematic reviewers minimize the potential for bias,[5, 16] and reassure readers 
that the choice of outcomes was not influenced by the results of individual clinical 
trials. That said, systematic reviewers are usually familiar with their field and a 
priori aware of potentially eligible clinical trials and/or how the outcome in 
question is frequently measured. Complete pre-specification also could improve 
efficiency in data abstraction and analysis during a systematic review. 
Systematic reviewers may also anticipate potential variation in outcomes 
across included clinical trials, and may allow for this by pre-specifying the 
elements of the outcome domain of interest in broad rather than specific terms 
(e.g., “visual acuity” versus “change in visual acuity from baseline to 1 year, as 
measured using a Snellen chart”). If such variation is suspected, systematic 
reviewers could explicitly state that all variations of a given element(s) will be 
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included. This could minimize the occurrence of what Page et al. refer to as 
“selective inclusion” in systematic reviews.[5] 
 We assume that primary outcomes for both clinical trials and systematic 
reviews are chosen based on perceived clinical importance and/or importance to 
patients; and that they are usually measured and reported more thoroughly than 
non-primary outcomes.[17] Not surprisingly, in our study, primary outcomes were 
more completely specified than other outcome types. Our estimate of 94.7% 
protocols pre-specifying a primary outcome is somewhat higher than the 88% that 
has been reported as pre-specified in clinical trial protocols,[18] and this could be 
related to the fact that we were examining protocols entered into software that 
requests the domain names of the pre-specified outcomes. 
 In our study, the most incompletely pre-specified outcome was quality-of-
life, a key patient-important outcome. This finding is concordant with other 
studies that have found that outcome reporting in clinical trials is a bigger problem 
for patient-important outcomes than other types of outcomes.[19]-[20] Further, 
when patient-important outcomes are not primary outcomes in clinical trials, the 
likelihood that reporting is complete is further reduced.[20] Our study aimed to 
evaluate the completeness and comparability of all outcomes, both patient-
important and not. 
 Our recommendation is that systematic reviewers should engage in 
discussion about and strongly consider pre-specifying all five elements of each 
outcome they wish to examine. When explicit pre-specification of all five 
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elements of a given outcome is not possible, for example when all possible options 
for a given outcome element are not known or are too numerous, the systematic 
reviewers should enumerate all known acceptable options for each element and 
explicitly state that all options for that element would be accepted, or provide 
rationale for why it is impossible to completely pre-specify an element. 
The Preferred Reporting Items for Systematic Reviews and Meta-analyses 
Protocols (PRISMA-P) is currently under development.[21] We hope that the 
availability of reporting guidelines (including details about outcome specification) 
will improve the completeness of specification of outcomes. Assuming that the 
Cochrane Collaboration recognizes the importance of completeness of pre-
specification, there are some possible ways to ensure that review authors are aware 
of the five elements of a completely specified outcome. First, editorial teams at 
Cochrane Review Groups (CRGs) should make all review authors aware of the 
five outcome elements early in the process (no later than the protocol development 
stage). Second, peer reviewers should be directed to consider whether the 
outcomes are completely pre-specified and not likely to have been chosen based 
on the strength and direction of the findings for those outcomes. Third, the 
Cochrane Handbook and other systematic review guidance materials, in addition 
to training workshops and other educational avenues, should incorporate explicit 
descriptions of all five outcome elements. Other organizations producing guidance 
on systematic review methodology (e.g., Agency for Healthcare Research and 
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Quality [AHRQ], the Centre for Reviews and Dissemination [CRD]) should also 
incorporate descriptions of the five outcome elements in their guidance materials.  
Organizations such as the Cochrane Collaboration suggest limiting the 
number of outcomes examined in a systematic review.[6] However, in order to 
evaluate whether the effect of an intervention persists over time, an otherwise 
identical outcome (i.e., identical in the other four elements) is often measured at a 
number of time-points. For the purpose of counting the number of outcomes 
measured, we recommend that these repeated measurements be counted as one 
outcome regardless of the number of time-points at which the outcome is assessed.  
 
Comparability of outcome elements 
In the era of evidence-based medicine, decision-makers in healthcare (e.g., 
patients, clinicians, and policy-makers) increasingly rely on systematic reviews. It 
is important that decision-makers have access to high quality and up-to-date 
individual systematic reviews as well as are able to compare results across 
systematic reviews. Cochrane “overviews” (Cochrane reviews which compile 
evidence from related reviews of interventions into a single accessible and usable 
document),[6] and network meta-analyses (analyses of three or more interventions 
for a given condition in one meta-analysis [22, 23]) are examples of formal 
comparisons across systematic reviews. To better feed into these formal 
comparisons and clinical practice guidelines, the elements of outcomes used in the 
various systematic reviews addressing a given condition should be comparable. In 
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our study, the largely incomplete pre-specification of outcomes in protocols 
restricted our ability to assess comparability in outcome elements across protocols. 
In cases where the various elements were specified, however, we observed 
variation in specific metrics and methods of aggregation. An example of such 
variation is: one protocol pre-specified that the outcome domain of visual acuity 
would be measured as mean change in visual acuity (number of letters) from 
baseline to one year, while another protocol pre-specified that visual acuity would 
be measured as percent of participants with improvement in visual acuity of at 
least three letters at one year. While both protocols specified the same outcome 
domain at the same time-point, differences in the specific metric (mean change 
versus value at a time-point) and method of aggregation (mean versus percent) 
would preclude a direct comparison of the visual acuity results. 
Efforts to promote comparability of outcomes across related clinical trials 
have led to the creation of core outcome measures within research fields.[24-26] 
One such effort is the Core Outcome Measures in Effectiveness Trials (COMET) 
Initiative,[27] whose investigators have produced guidance on methods for 
identifying core outcome sets.[28] Because the issue of comparability of outcomes 
across systematic reviews is complex, we recommend that researchers within a 
field (e.g., systematic reviewers, Cochrane review group editors, clinical trialists) 
and patients consider developing comparable outcomes across systematic reviews, 
adding to a core list over time as appropriate.   
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There are pros and cons of establishing comparability in outcomes across 
reviews, however. Increased comparability will likely facilitate formal 
comparisons across systematic reviews and development of clinical practice 
guidelines. In addition, decision-makers would be better able to compare more 
directly the effectiveness of treatment options. For example, hundreds of 
measurement scales (specific measurements) have been used to assess mental 
status in schizophrenia [29] and quality-of-life,[30] making comparability across 
clinical trials very challenging. Finally, use of comparable outcomes could 
discourage authors from ‘cherry-picking’ outcomes to be used in their studies.[31]  
 On the other hand, comparability across reviews is not always possible or 
desirable. Limiting outcomes to those used by previous researchers risks excluding 
an outcome that is in fact important, or authors may be compelled to include an 
outcome that they do not consider important. Additionally, it might not be possible 
to identify a priori all relevant outcomes and outcome elements for a rapidly 
evolving field or for a field with a large number of relevant outcomes.  
 
Availability of protocols and amendments to protocols 
 We were unable to obtain 3/57 (5.3%) protocols associated with our sample 
of Cochrane reviews. This poses a concern for investigators conducting 
methodological research in systematic reviews, and for users of systematic 
reviews generally. Although we do not believe that relying on the Methods 
sections of three completed Cochrane reviews in the cases where we could not 
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find the protocols is likely to have influenced our findings, we believe that all 
protocols and previous versions of completed systematic reviews should be made 
available to researchers. Furthermore, an updated protocol was published for only 
one of the protocols we examined. The Cochrane Collaboration should consider 
keeping all protocols up-to-date by publishing updated versions of protocols or 
publishing protocol amendments for all its reviews. In this way, Cochrane review 
protocols would be formally amended in the same way that clinical trial protocols 
are amended and made available, providing an accessible audit trail.  This practice 
will facilitate Cochrane's contribution of its protocols and updates to 
PROSPERO,[32, 33] an international database of prospectively registered 
systematic reviews.  
Our focus on Cochrane reviews is both a strength and a limitation. 
Assuming that Cochrane reviews are among the most rigorously conducted and 
reported systematic reviews,[34, 35] it is likely that completeness and 
comparability of outcomes are higher in our sample of reviews than in other 
reviews. It would be useful to know how others producing systematic reviews 
(e.g., AHRQ, CRD, independent authors) choose and describe outcomes in their 
systematic reviews. 
As discussed, we did not examine the individual clinical trials examined by 
each Cochrane review in our sample to learn more about the source of non-
comparability in outcome elements. Nor did we test for empirical evidence of 
outcome reporting bias on the part of the systematic reviewers. Because our 
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assessments of completeness and comparability were based on what was reported 
in the protocols (and some completed reviews), it is possible that our findings 
were a consequence of unsatisfactory reporting and that the rationale for the 
outcomes chosen could not be determined without asking the systematic review 
authors directly.  
Our study should be replicated in other disease areas and on a larger scale 
to assess the applicability of our findings to other fields. Although we have 
compared the outcomes pre-specified in the protocol with what is in the 
corresponding completed review’s Methods section, a next step would be to 
compare the outcomes in the Methods with those in the Results section. This 
would allow a confirmation of the potential bias by systematic reviewers that has 
been demonstrated by Kirkham et al. using a cohort of Cochrane reviews [36] and 
by various investigators studying this issue in clinical trials.[14, 17, 37, 38] 
 
Conclusions 
We recommend that systematic review authors strongly consider pre-
specifying all outcomes of interest using the five elements of a completely 
specified outcome (domain, specific measurement, specific metric, method of 
aggregation, and time-points), amending the protocol formally, as needed. We 
further suggest that researchers and other stakeholders, such as patients, carefully 
consider the pros and cons of establishing comparability in outcomes across 
systematic reviews addressing a given condition.   
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Table 3-1: Number of protocols and outcome domains by condition, year 
published, and whether specified as primary outcome 
 




All   571 (100) 1452 (100) 
Condition addressed    
   Glaucoma  22 (38.6) 51 (35.2) 
   Cataract  16 (28.1) 35 (24.1) 
   Age-related macular degeneration (AMD)  15 (26.3) 47 (32.4) 
   Diabetic retinopathy (DR)    4   (7.0) 12   (8.3) 
Year of protocol publication     
   2000 or earlier  6  (10.5) 13   (9.0) 
   2001 to 2005  15 (26.3) 37 (25.5) 
   2006 to 2010  29 (50.9) 76 (52.4) 
   2011 or later   7  (12.3) 19 (13.1) 
Type of outcomes domain specified  Not applicable  
 
   Outcomes specified as primary  48 (33.1) 
   Outcomes specified as non-primary   88 (60.7) 
   Type of outcome unclear   9   (6.2) 
1 54 protocols and 3 completed reviews; One protocol did not include any of the outcome domains selected for detailed 
data extraction 
2 139/145 of the outcomes were described in the 54 protocols. 
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Table 3-2: Completeness (number of completely-specified elements out of five 
possible) by outcome domain 
Characteristic  Number (%) 
of protocols 
Median (IQR) number 
of completely-specified 
elements per outcome 
p-value 
 
All   571 (100) 3.0 (2.0 - 4.0) - 
Outcome domain     
   Quality-of-life  47 (82.5) 1.0 (1.0 - 2.0)  
   Visual acuity  47 (82.5) 3.0 (2.0 - 4.0)  
 
0.0001    Intraocular pressure  21 (36.8) 4.0 (3.0 - 4.0) 
   Disease progression  15 (26.3) 3.0 (2.0 - 4.0) 
   Contrast sensitivity  15 (26.3) 2.0 (1.0 - 3.0)  




Table 3-3: Completeness (number of completely-specified elements out of five 
possible) by type of protocol/outcome 
Characteristic  Median (IQR) number of 
completely specified elements 
per outcome 
p-value 
All1  3.0 (2.0 - 4.0) NA 
Condition addressed      
   Glaucoma  3.0 (2.0 - 4.0)  
 
0.1218    Cataract  3.0 (2.0 - 4.0) 
   Age-related macular degeneration (AMD)  2.0 (1.0 - 3.0) 
   Diabetic retinopathy (DR)  3.0 (1.5 - 4.0) 
Year of protocol publication       





   2001 to 2005  2.0 (2.0 - 4.0) 
   2006 to 2010  3.0 (2.0 - 4.0) 
   2011 or later   2.0 (2.0 - 3.0) 
Type of outcome domain specified    
   Outcomes specified as primary  4.0 (3.0 - 4.0)  
0.0001 
   Outcomes specified as non-primary   2.0 (1.0 – 3.0) 
   Type of outcome not specified   1.0 (1.0 – 2.0)  
1 54 protocols and 3 completed reviews; Median 3.0 (2.0 – 4.0) for outcomes in the 54 protocols and 1.5 (1.0 – 2.0) for 




Table 3-4: Examples of incomplete outcome pre-specification 
 Exact text from methods section of protocol Number of 
completely-
specified elements 
(out of five 
possible) 
The primary outcome for the review will be visual acuity. 
 1 
When available quality of life data will be described for those with 
operated and unoperated cataract. 1 
Postoperative visual acuity 
 1 
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Previous research has shown that discrepancies exist between information 
presented in conference abstracts (“abstracts”) and corresponding full publications 
of the same randomized controlled trial (RCT). Conflicts of interest are prevalent 
in biomedical research. However, the association between author conflicts of 
interest and full publication of RCTs is unclear.  
 
Objectives 
Using RCTs in ophthalmology as an example, evaluate: (1) the agreement in 
reported main outcome results comparing abstracts and their corresponding full 
publications; and (2) the association between author conflicts of interest and full 
publication of results presented in abstracts. 
 
Methods 
We included all abstracts presented at the 2001-2004 Association for Research in 
Vision and Ophthalmology (ARVO) conferences describing results of RCTs. 
Through electronic searching and emailing abstract authors, we identified the 
earliest full publication (journal article) containing results of each abstract’s main 
outcome, through 2013. We defined the “main” outcome as the specified primary 
outcome, or when it was not specified or when more than one were specified, we 
selected (in this order) the outcome mentioned in the Title, the Objective, or the 
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outcome mentioned first in the Results. To evaluate agreement between the 
abstract and its paired full publication in main outcome results, we categorized 
discordance into qualitative (difference in direction of statistical significance) or 
quantitative (<10%, 10-20%, >20%, or amount unclear). We used the ARVO 
classification of conflicts of interest: having financial interest; being an employee 
of a business with interest; being a consultant to a business with interest; being an 
inventor/developer with patent; and receiving at least one gift in the past year. 
Using log-binomials, we calculated the relative risk (RR) of publication associated 
with each conflict of interest in an overall analysis (model 1) and an interaction 
analysis (model 2) separately for abstracts with main outcomes statistically 
significant, not statistically significant, and not reported. 
 
Results 
We included 513 abstracts, of which 230 (44.8%) were published in full. Median 
time from presentation to publication was 18 months (interquartile range 
[IQR]=11 to 33 months). Among the 86 abstract/full publication pairs with the 
same main outcome at the same time-point, there was either quantitative or 
qualitative discordance in 47 pairs (54.7%): qualitative discordance in 7 pairs and 
quantitative discordance in 40 pairs (quantitative discordance <10%, 10%-20%, 
>20%, and of unclear amount in 14, 5, 14, and 7 pairs respectively). First author 
reporting at least one conflict of interest was associated with greater likelihood of 
publication (RR=1.31; 95% CI=1.04 to 1.64) and shorter time to publication (log 
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rank p=0.026). Specific first author conflicts of interest associated with publication 
were receiving financial support (RR=1.50; 95% CI=1.19 to 1.90) and receiving at 
least one gift from industry in the past year (RR=1.42; 95% CI=1.05 to 1.92). 




There was either qualitative discordance or some amount of quantitative 
discordance in main outcome results in the abstract and the full publication for 
more than half of the pairs. Irrespective of main outcome results, a declared 
conflict of interest of the abstract’s first author (specifically, receiving financial 
support and at least one gift from industry in the past year) was associated with 




There are three main groups of individuals impacted by results of 
randomized controlled trials (RCTs) presented at conferences: clinicians, patients, 
and those synthesizing all available research, systematic reviewers. RCT results 
presented at conferences directly impact clinicians and patients because clinical 
decisions are sometimes based solely on results presented as conference abstracts 
(“abstracts”).[1-3] For example, Gross and colleagues documented that pre-
publication dissemination of results promptly led to substantial changes in clinical 
practice associated with carotid endarterectomy.[2] RCT results presented at 
conferences indirectly impact clinicians and patients through systematic reviews. 
Systematic reviews of RCTs are considered the strongest form of evidence for the 
effectiveness of healthcare interventions,[4] and underpin evidence-based clinical 
practice guidelines and other policy-related decision-making. When study results 
presented in a conference abstract have not been published in full, it is 
recommended that systematic reviewers include those results.[5-7]  
Due to the impact of conference abstracts on clinical decision-making and 
systematic reviews, it is vital that clinicians, patients, systematic reviewers, and 
other users of systematic reviews can depend on information presented in 
abstracts. The concerns are that abstracts do not typically undergo full peer 
review; might contain preliminary results of RCTs; and might not contain 
sufficient information to assess the methodological quality of the RCT.[8] Indeed, 
research has shown that 40% to 62% of RCTs either changed, introduced, or 
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omitted at least one primary outcome between the protocol and publication 
stages.[9, 10] Research has also demonstrated discrepancies in analysis methods 
when comparing an RCT’s publication to other documents such as the protocol 
and trial registry entries. These discrepancies include types of subgroup analyses 
(61% to 100%) and statistical adjustment (46% to 82%).[10] Similarly, study 
results have been shown to be discrepant when comparing abstracts with full 
publications of the same RCT. In ophthalmology, 34% of primary outcomes 
reported in abstracts had not been specified as such in ClinicalTrials.gov, a major 
clinical trials registry.[11] Studies in the fields of orthopedics,[12, 13] 
cardiology,[14] pediatrics,[15] pediatric surgery,[1] and infectious disease[16] 
have shown that 40% to 60% of RCTs report discrepant results in primary 
outcome results comparing abstracts and full publications. These comparisons, 
based on abstracts that reach full publication, shed light on whether abstracts that 
do not reach full publication should be considered sources of dependable 
information about RCTs. 
Abstracts that do get published are not a random sample of all abstracts, 
however. We do know that certain study-level characteristics are associated with 
full publication. Industry funding has been shown to be associated with greater 
likelihood of full publication [17-19] and, when RCTs are fully published, more 
favorable study results.[20-23] The impact of study investigator conflicts of 
interest is less clear, however. Conflicts of interest refer to the set of conditions in 
which professional judgment concerning a primary interest (such as a patient’s 
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welfare or the validity of research) might be unduly influenced by a secondary 
interest (such as financial gain).[24, 25] 
 Real and perceived financial conflicts of interest are prevalent in 
biomedical research. A survey of academic investigators found that approximately 
28% received industry support for their research, 43% received research-related 
gifts, and 33% had personal financial ties with industry.[26] In a separate survey 
of clinical practice guideline development panel members, 52% reported having 
some form of financial association with industry, representing a conflict of 
interest.[27]  
Among RCTs that are published, the presence of conflicts of interest is 
associated with greater likelihood of the authors’ conclusions favoring 
experimental interventions.[28] The potential impact of conflicts of interest on the 
likelihood of publication appears complex, though. On one hand, financial gain 
might threaten impartial judgment,[29] leading to RCT authors selectively 
publishing RCTs, or rushing them to publication, based on the results (publication 
bias),[30-32] or even selectively reporting certain outcomes in the publications 
(outcome reporting bias).[9, 10, 32-35] On the other hand, the monetary gain 
associated with having a financial relationship with industry might facilitate 
publication, irrespective of study results. 
 One step of the RCTs results dissemination process during which 
publication bias, outcome reporting bias, and the impact of conflicts of interest 
might operate is between presentation of results at a conference and full 
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publication of those results in journal articles.[36, 37] Conferences offer an 
important platform for presenting results of RCTs. Presentation is a goal either 
because it represents an opportunity to disseminate results, or, because the authors 
wish to attend the conference and the submitted abstract is a means to attend. In 
most cases, it is difficult to interpret whether publishing in full was a goal of the 
authors. Indeed, publication not being a goal is frequently reported by authors as a 
reason for not publishing abstracts in full.[37] 
  
OBJECTIVES 
We conducted a study of RCTs in ophthalmology to evaluate: (1) the 
agreement in reported main outcome results comparing abstracts and their 
corresponding full publications; and (2) the association between author conflicts of 
interest and full publication of results presented in abstracts. 
 
METHODS 
Included abstracts  
We included all abstracts describing results of RCTs presented at the 2001-
2004 Association for Research in Vision and Ophthalmology (ARVO) 
conferences. This annual conference is the largest international research 
conference in vision science. Researchers present studies of various designs 
addressing basic science and various clinical conditions. We considered eligible 
for this study RCTs addressing any type of intervention for any clinical condition 
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or for healthy volunteers. We excluded abstracts of non-RCTs or abstracts of 
RCTs where only non-randomized comparisons were made. Because we did not 
obtain individual human subjects data, the Johns Hopkins Bloomberg School of 
Public Health Institutional Review Board (IRB) determined that IRB approval was 
not needed (IRB #00001810). 
 
Identifying full publications  
We searched for the earliest full publication (journal article) containing 
results of each abstract’s main outcome. We employed two strategies to identify 
full publications: 
1. We searched the following electronic databases: MEDLINE, Cochrane Central 
Register of Controlled Trials (CENTRAL), EMBASE, Latin American and 
Caribbean Health Sciences Literature (LILACS), Web of Science, and 
SCOPUS. We searched by abstract author (in this order: first, second, last, and 
then remaining authors), combined with at least one unique search term 
(derived from the abstract). If no article was identified, we repeated the search 
with at least two other search terms coupled with each author, in the order 
described above. We limited the search to two years before the abstract was 
presented, through June 2013.  
2. When full publications were not identified through electronic searches, or if 
insufficient information was provided in the abstract and/or full publication to 
confirm a match, we contacted authors of the abstracts via e-mail in April 
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2009, asking them if the RCT presented in the abstract was published in full. 
E-mail addresses were retrieved from publicly available sources (e.g., PubMed, 
Google®, academic websites) and from the ARVO member directory.  
 
Data extraction   
 We developed a data extraction form for both abstracts and full publications 
using the Systematic Review Data Repository (SRDR) (http://srdr.ahrq.gov). 
SRDR is an open-access web-based data system that allows structured and 
organized data extraction through remote and simultaneous access by multiple 
users. We pilot-tested the data extraction form with both abstracts and full 
publications, and revised it as needed before data extraction. For each abstract and 
full publication, we extracted information on author characteristics (authorship 
order, primary affiliations, and conflicts of interest), study characteristics, study 
design, participants, interventions, comparisons, and all outcomes. Two 
investigators extracted data about each abstract and full publication independently, 
and resolved discrepancies through discussion. 
 
Identifying the “main” outcome 
 Because abstracts and full publications of RCTs do not always specify the 
“primary” outcome(s), we developed an algorithm a priori to classify a reported 
outcome as the main outcome in this order:  
133 
1. If only one primary outcome was specified, we selected that outcome as the 
main outcome. 
2. If more than one primary outcome was specified, we selected the first 
outcome among them with results in the Results as the main outcome. 
3. If no primary outcome was specified, we selected the outcome mentioned 
in the Title or Objective as the main outcome. 
4. If no primary outcome was specified and no outcome was mentioned in the 
Title or Objective, we selected the first outcome with results in the Results 
section as the main outcome.  
 
Classifying statistical significance of results for the main outcome 
 For the main outcome in each abstract and full publication, we extracted 
all reported results data at the last available time-point, including individual 
treatment group (“arm”) data, between-arm effect estimate, 95% confidence 
intervals, and p-value. We considered results for the main outcome as statistically 
significant if the effect estimate, 95% confidence interval, or p-value was 
statistically significant at the 5% level for at least one reported between-arm 
comparison for the main outcome (favoring either the experimental arm or the 
control arm); and not statistically significant if not statistically significant at the 
5% level for each reported between-arm comparison for the main outcome. When 
insufficient data were reported for between-arm comparisons, or when the authors 
only stated that results were statistically significant without reporting the effect 
134 
estimate, 95% confidence interval, or p-value, we considered statistical 
significance of results as not reported.  
 While our main analysis focused on the main outcome, we also evaluated 
statistical significance for all other outcomes. 
 
Evaluating agreement in main outcome results between abstracts and 
corresponding full publications 
 For each abstract/full publication pair, we first determined whether the 
main outcome was the same and reported at the same time-point in both 
documents. For each pair in which the main outcome was the same and statistical 
significance of results for the main outcome was reported, we evaluated whether 
the results agreed.  
We defined discordance as either qualitative or quantitative. Qualitative 
discordance refers to a difference in the direction of the effect estimate or 
statistical significance of the p-value. For example, a difference in direction may 
imply that the effect estimate/p-value was statistically significant (p<0.05) in the 
abstract and not statistically significant in the full publication (or vice versa), or 
that one intervention arm was statistically significantly favored in the abstract and 
another arm was statistically significantly favored in the full publication.  
Quantitative discordance of an effect estimate for the main outcome refers 
to any difference in the magnitude but not in the direction of effect estimates, 
when comparing the abstract with the full publication. Specifically, for each 
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abstract/full publication pair, we calculated percent difference in reported effect 
estimates as follows:  
𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃
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We categorized quantitative discordance based on the percent differences: 
<10%, 10%-20%, and >20%. When effect estimates were reported in both the 
abstract and full publication, we used the reported effect estimates to make the 
comparison. When effect estimates were not reported in one or both of the two 
reports in the matched pair, but sufficient information was reported to calculate 
effect estimates, we calculated effect estimates. When only p-values were reported 
(without effect estimates or sufficient information to calculate effect estimates), 
any difference in p-value without a difference in the direction of statistical 
significance (at the 5% level) also qualified as quantitative discordance; we 
categorized these instances as ‘quantitative discordance – amount unclear’.  
 
Classifying author conflicts of interest  
 We adopted the financial conflicts of interest classification system used 
by ARVO in 2001 through 2004. This system classifies conflicts of interest into 
six types: receiving financial support (F); having personal financial interest (I); 
being an employee of a business with interest (E); being a consultant to a business 
with interest (C); being an inventor/developer with patent (P); and receiving at 
least one gift from a business with interest in the past year (R). Further explanation 
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about these types of conflicts of interest is provided in Box 4-1. For year 2001, 
conflicts of interest data were presented only as aggregated information for the 
entire author team. Starting in 2002, ARVO required disclosure of conflicts of 
interest separately for each author of an abstract, and we extracted all disclosed 
conflicts of interest for each author. 
 
Statistical analysis 
To evaluate the agreement in main outcome results in abstract/full 
publication pairs, we calculated the frequency with which each form of 
discordance occurred.  
To examine the association between conflicts of interest and full 
publication, we calculated relative risks (RR) of publication of abstracts using log-
binomial models. To examine whether the association between conflicts of interest 
and full publication depended on the statistical significance of results for the 
abstract’s main outcome, we used both overall models (model 1) and interaction 
models (model 2). Model 2 contained terms for the interaction between the 
specific conflict of interest and (1) whether or not statistical significance of results 
for the main outcome was reported in the abstract, and (2) whether or not results 
for the main outcome in the abstract was statistically significant.  
We plotted Kaplan-Meier curves depicting the cumulative probability of 
full publication of abstracts over time (in months). We conducted log rank 
significance tests of differences in probability of publication at any time point 
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during follow-up.[38] We classified abstracts that were published before or at the 
time of presentation at the conference as being published within one month of 
presentation. 
All statistical analyses were conducted using STATA® 12. 
 
RESULTS 
Included abstracts  
 A total of 20,721 abstracts were presented at ARVO during years 2001-
2004, of which 545 abstracts (2.6%) described results of RCTs (Figure 4-1). We 
excluded 32 of these 545 abstracts because they only described non-randomized 
comparisons nested within RCTs. We included the remaining 513 abstracts in this 
study. 
 
Specification of main outcome in included abstracts 
Among the 513 abstracts, 49 abstracts (9.6%) specified one primary 
outcome, 15 abstracts (2.9%) specified more than one primary outcome, and 449 
abstracts (87.5%) did not specify any primary outcome. We selected the single 
specified primary outcome as the main outcome for 49 abstracts (9.6%), the 
outcome mentioned in the Title or Objective as the main outcome for 318 abstracts 
(62.0%), and the outcome mentioned first in the Results section as the main 
outcome for the remaining 146 abstracts (28.5%). 
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Statistical significance of results for the main outcome in included abstracts 
Statistical significance of results for the main outcome was not reported for 
285/513 abstracts (55.6%) (Table 4-1). When it was reported, results for the main 
outcome were statistically significant in 117/228 abstracts (51.3%). Most of the 
abstracts reporting statistically significant results for the main outcome favored the 
experimental rather than the control arm (102/117 abstracts, 87.2%).  
 
Evaluating agreement in main outcome results between abstracts and 
corresponding full publications 
 Among all 513 abstracts, 230 (44.8%) were published in full. Median time 
from conference presentation to full publication was 18 months (interquartile 
range (IQR)=11 to 33 months, range=1 to 90 months). After approximately 60 
months, the cumulative proportion of abstracts that was published reached a 
plateau (Figure 4-2a).  
 We could not use all 230 pairs of abstracts and corresponding full publications 
to evaluate agreement in main outcome results. For 190/230 pairs (83.6%), the 
main outcome was the same in the two reports. Main outcomes were more likely 
to be the same if the results of the main outcome in the abstract were statistically 
significant compared with not statistically significant or not reported (RR=1.8; 
95% CI=1.09 to 1.28). Among the 190 pairs in which the main outcome was the 
same, the last available time-point in the abstract was not reported in the full 
publication for 104 pairs (54.7%). Among these 104 pairs, we determined that the 
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RCT was ongoing (still following participants) when the abstract was written for 
19 pairs (18.3%). For evaluation of agreement in results, we used the 86 pairs for 
which results for the main outcome were reported in both the abstract and the full 
publication at the same time-point.  
 Among the 86 pairs, 39 (45.3%) exactly agreed, while there was some form of 
discordance in the remaining 47 (54.7%): quantitative discordance in 40 pairs and 
qualitative discordance in 7 pairs (Figure 4-3, left). Among the 40 pairs with 
quantitative discordance, discordance was <10% in 14 pairs, 10%-20% in 5 pairs, 
and >20% in 14 pairs. In 7 pairs, there was quantitative discordance, but the 
amount was unclear because only p-values were reported in the abstract and/or full 
publication. 
 If we defined agreement as exact agreement or <10% of discordance, 
agreement would be observed for 53 pairs (61.6%), and some form of discordance 
would be observed for 33 pairs (38.4%) (Figure 4-3, right). 
 
Association between RCT characteristics and full publication  
Abstracts that were presented as oral presentations were more likely to be 
published than abstracts presented as posters (RR=1.25; 95% CI=1.01-1.56). For 
the time period we examined, 2001-2004, ARVO did not require that authors of 
conference abstracts disclose the study’s funding source. A little more than half of 
the abstracts reported a funding source (271/513 abstracts, 53.0%), and among 
them, 114/271 abstracts (41.9%) explicitly reported receiving no funding (Table 4-
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1). Proportions of abstracts reporting industry, government, and other funding 
were similar (20.7%, 26.1%, and 21.7% respectively). Most abstracts (361/513 
abstracts, 70.4%) did not report whether the RCT was single center or multicenter. 
Among the abstracts that did, more abstracts described multicenter RCTs (106/152 
abstracts, 69.7%) than single center RCTs (46/152 abstracts, 30.3%). 
Funding source was associated with full publication. Abstracts describing 
RCTs that were not funded were less likely to be published compared with other 
abstracts (RR=0.76; 95% CI=0.58 to 0.99). Abstracts describing RCTs that 
received industry funding were more likely to be published than those that did not 
(RR=1.42; 95% CI=1.12 to 1.79). Similarly, abstracts describing RCTs that 
received government funding were more likely to be published than those that did 
not (RR=1.31; 95% CI=1.04 to 1.65). These findings are reflected in shorter time 
to publication for abstracts of funded RCTs compared with abstracts those of 
unfunded RCTs and abstracts with funding not reported (log rank p=0.021) 
(Figure 4-2b). 
Abstracts describing multicenter RCTs were more likely than single-center 
RCTs to be published (RR=1.79; 95% CI=1.15 to 2.80). Abstracts of multicenter 
RCTs also had shorter time to publication than abstracts of single-center RCTs and 





Association between statistical significance of results and full publication  
 Abstracts reporting whether results for the main outcome were statistically 
significant were more likely to be published in full (RR=1.44; 95% CI=1.19 to 
1.74), and were published sooner (log rank p<0.001) (Figure 4-2d) compared with 
abstracts which did not report statistical significance. Among abstracts reporting 
statistical significance of results for the main outcome (n=228 abstracts), there was 
no statistically significant association between statistical significance of results 
and full publication (RR of publication comparing statistically significant with 
statistically non-significant results=0.97; 95% CI=0.76 to 1.24). Time to 
publication was similar comparing abstracts with statistically significant and 
statistically non-significant results for the main outcome (Figure 4-2e). 
  Abstracts reporting whether results for any (main or non-main) outcome were 
statistically significant were more likely to be published (RR=1.51; 95% CI=1.24 
to 1.84) compared with abstracts not reporting statistical significance for any 
outcome. Among abstracts reporting statistical significance of results for at least 
one outcome (n=249 abstracts), the likelihood of publication was similar 
comparing abstracts reporting at least one statistically significant outcome and 





Assumption-based analyses of association between statistical significance of 
results for the main outcome and full publication 
 Because a large proportion of the abstracts did not report statistical 
significance of results for the main outcome, we evaluated the association between 
statistical significance of results for the main outcome and full publication under 
five different hypothetical scenarios (Figure 4-4). When we assumed the results 
for the main outcome were statistically significant in 100% (assumption 1), 75% 
(assumption 2), or 50% (assumption 3) of abstracts not reporting statistical 
significance of the main outcome, the associations between significance of results 
and full publication were statistically significant or borderline statistically 
significant (RR=1.31, 95% CI=1.07 to 1.60; RR=1.28, 95% CI=1.06-1.55; and 
RR=1.22; 95% CI=1.00 to 1.48 respectively). When we assumed the main 
outcome results were statistically significant in 25% of those abstracts (assumption 
4), the association between significance of results and full publication was not 
statistically significant. An inverse association was observed when we assumed 
the main outcome results were statistically significant in none of those abstracts 
(RR=0.80; 95% CI=0.65 to 0.99) (assumption 5).  
 
Affiliations of authors of included abstracts 
The most frequent primary affiliation of abstract first authors was an 
academic institution (311/505 abstracts, 61.6%) (Table 4-1). Compared with last 
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authors, first authors less frequently reported primary affiliation with industry 
(6.1% vs. 17.8%).  
 
Difference in authorship comparing abstracts and full publications  
 Among the 230 pairs of abstracts and corresponding full publications, there 
was at least one difference in authorship in 202 pairs (87.8%) (Table 4-2). Only 
middle (i.e., non-first and non-last) authors changed in 44 pairs (19.1%). In 85 
pairs, either the first author (33 pairs, 14.4%) or last author (52 pairs, 22.6%) 
changed, but not both. In 36 pairs, some form of exchange between first and last 
author took place: they swapped positions in 6 pairs (2.6%), last author became 
first author in 15 pairs (6.5%), and first author became last author in 15 pairs 
(6.5%). In 37 pairs (16.7%), neither did the first and last author retain their 
position nor did they take each other’s position.  
 Overall, the first author and was removed from the full publication in 
36/230 pairs (15.6%). The second author was removed in 41/230 pairs (17.8%). 
 
Conflicts of interest of authors of included abstracts 
For approximately one-third of the abstracts, at least one author reported 
having at least one conflict of interest (177/513 abstracts, 34.5%). Financial 
support (99/513 abstracts, 19.3%) and employment by a business with interest 
(76/513 abstracts, 14.8%) were reported most frequently. Examining the conflicts 
of interest separately for first and last authors suggests similar distributions to 
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those of any author. However, compared with last authors, first authors more often 
reported receiving financial support (18.8% vs. 9.0%), and less often reported 
employment by a business with interest (4.3% vs. 13.9%). 
 
Associations between conflicts of interest and full publication – Overall analysis 
(model 1) 
Overall, when looking at the first author, but not the last author or ‘any’ 
author, reporting at least one conflict of interest appeared to be associated with full 
publication. In model 1, abstracts whose first author reported having at least one 
conflict of interest had greater likelihood of publication (RR=1.31; 95% CI=1.04 
to 1.64) (Table 4-3) and a statistically significantly shorter time to publication (log 
rank p=0.026) (Figure 4-2f) compared with abstracts whose first author reported 
no conflicts of interest. A positive association between conflicts of interest and full 
publication was not observed for the last author or for ‘any’ author (Table 4-3 and 
Figures 4-2g and 4-2h). 
Regarding specific conflicts of interest, abstracts with first author reporting 
receiving financial support from industry (RR=1.50; 95% CI=1.19 to 1.90) or at 
least one gift from industry within the past year (RR=1.42; 95% CI=1.05 to 1.92) 
were more likely to be published in full compared with abstracts with first author 
not reporting these conflicts of interest.  
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Associations between conflicts of interest and full publication – Interaction 
analysis (model 2) 
 Table 4-3 shows results from an analysis of interaction between conflicts of 
interest and statistical significance of results for the main outcome in the abstract 
(model 2). Generally, model 2 estimates of RR of publication for each subgroup of 
abstracts were similar to model 1. This was supported by the fact that none of the 
interaction terms were statistically significant, suggesting that the associations 
between conflict of interest and publication did not differ based on whether the 
statistical significance of results for the main outcome in the abstract were not 
statistically significant, statistically significant, or not reported. For example, the 
first author receiving financial support from industry was associated with 50% 
higher likelihood of publication in model 1, while the corresponding estimates 
were 44%, 37%, 11% for abstracts with statistically significant results, without 




 In this longitudinal study of 513 abstracts of RCTs presented at the world’s 
largest ophthalmology research conference (ARVO), we have demonstrated that 
there was either qualitative or quantitative discordance in results for the main 
outcome comparing the abstract with the full publication for approximately 55% 
of pairs. As regards conflicts of interest, abstracts with first authors reporting at 
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least one conflict of interest were 31% more likely to be published, and were 
published sooner, compared with abstracts with first author not reporting any 
conflict of interest. This association did not depend on whether the results for the 
main outcome in the abstract were statistically significant, statistically non-
significant, or whether the statistical significance of the association was reported.  
 
Dependability of conference abstarcts: Implications for clinicians, patients, and 
systematic reviewers 
 The discordance between results of main outcomes presented in abstracts and 
full publications is worrying. For almost one in five (16.4%) pairs of abstracts and 
full publications, the main outcomes were different in the two reports. When the 
main outcome was indeed the same, results for the outcome’s last time-point in the 
abstract were not reported in the full publication for more than half of the pairs 
(54.7%). When the same main outcome was reported at the same time-point, 
approximately 8% of abstract/full publication pairs reported qualitatively different 
results in the two reports. This implies that if a decision-maker was using an RCT 
to make a treatment decision, approximately one in twelve such treatment 
decisions based on the same outcome could differ depending on whether the 
decision-maker looked at the abstract or the full publication.  
 Even when there was no qualitative discordance, almost half of the 
abstract/full publication pairs reported quantitatively different results for the same 
main outcome. When discordance could be quantified, we classified it into three 
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categories based on cutoffs at 10% and 20%. We recognize that these cutoffs are 
arbitrary, but the amount of discordance that might be tolerated likely depends on 
the field and the context in which the results are used. For example, estimates of 
RR of 1.3 and 1.5 from a single RCT might not readily be considered meaningful 
by decision-makers, but might impact whether the summary effect estimate might 
or might not overlap null in a meta-analysis. This might especially be true if effect 
estimates obtained from abstracts are based on preliminary analyses, and therefore, 
might be based on smaller sample sizes and have wider confidence intervals. In 
our study, results being preliminary could have explained for less than 20% of the 
discrepancies we observed. Discrepancies become especially problematic for a 
new clinical intervention, where, for example, a health plan may ask systematic 
reviewers for a summary of available evidence so as to allow a treatment 
reimbursement decision. In this example, if most of the evidence is reported in 
abstracts, and the individual effect estimates are consistently inflated, this could 
impact decision-making.    
 Our findings of discordances between abstracts and full publications (among 
published abstracts) suggest that it is conceivable that the dependability of 
abstracts might be even less for abstracts that are not published.  
 The Institute of Medicine (IOM), the Cochrane Collaboration, and the Agency 
for Healthcare Research and Quality (AHRQ) all recommend that, when study 
results are not available from publications, systematic reviews include results from 
both unpublished sources, such as abstracts.[5-7] In a systematic review, there are 
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a few possible scenarios and typical strategies for a certain outcome from a certain 
RCT:  
• Scenario 1: Results for the outcome are only available from an abstract. The 
systematic reviewer typically includes the data from the abstract in the meta-
analysis, and should conduct a sensitivity analysis to examine whether 
excluding the data affects the meta-analytic effect estimate.[8]  
• Scenario 2: Results for the outcome are available from both an abstract and a 
full publication, and the data exactly agree. This is the ideal scenario, and it 
does not matter from where the systematic reviewer obtains the data. 
• Scenario 3: Results for the outcome are available from both an abstract and a 
full publication, and there is quantitative discordance. The systematic 
reviewer typically includes the data from the full publication. However, in 
doing so, the systematic reviewer makes the implicit assumption that the full 
publication includes the more valid data.  
• Scenario 4: Results for the outcome are available from both an abstract and a 
full publication, and there is qualitative discordance. The systematic reviewer 
typically makes the same assumption as in Scenario 3 and includes data from 
the full publication. 
The findings in our study suggest that when results presented in an abstract 
are published in full (i.e., when scenarios 2, 3, and 4 are possible), discordance 
(scenarios 3 and 4) is more common than exact agreement (scenario 2). The 
existence of discordance has two main implications. First, when only an abstract is 
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available (scenario 1), the systematic reviewer should be cautious about including 
the results therein, running the appropriate sensitivity analysis.[8] The documented 
high prevalence of discordances in our study and previous research also supports 
this approach.[1, 12-16] Second, when both abstract and full publication are 
available and the data are discordant (scenarios 3 and 4), the systematic reviewer 
should contact the authors, seeking clarification about the results before 
proceeding. This is especially critical in instances of qualitative discordance 
(scenario 4). 
 
Conflicts of interest, statistical significance of main outcome results in abstracts, 
and full publication 
 Prior research has demonstrated that outcomes in RCTs are selectively 
reported [33-35] or under-reported [10] based on the direction of the results, 
leading to outcome reporting bias. Our finding of no association appears to be at 
odds with this and other research focusing specifically on publication of the main 
outcome.[19, 39, 40] We believe that the likely reason why our findings differed 
was that statistical significance of results for the main outcome was not reported 
for more than half of the abstracts in our study (55.6%), and we did not consider 
these abstracts in our main analysis. Thus, the abstracts in our study not reporting 
the statistical significance of results for the main outcome are likely not a random 
sub-set of all abstracts in our study. Indeed, when we subjected our data to 
different assumptions for the missing results, we observed results similar to those 
150 
found by others. For example, even if we assumed that 50% of abstracts with 
statistical significance not reported were, in fact, statistically significant 
(assumption 3), abstracts with statistically significant results for the main outcome 
were 22% more likely to be published than abstracts with non-statistically 
significant results for the main outcome. Given what we know about outcome 
reporting bias, and that approximately half of all reported main outcomes in our 
study were statistically significant, it is likely that in abstracts not reporting 
statistical significance, less than half of the main outcomes were actually 
statistically significant (therefore, assumptions 1 and 2 are more reasonable). 
 Our finding that conflicts of interest of the first author impact publication 
more than those of the last author is intriguing. We explored a few potential 
reasons why this might have occurred. First, financial support in the form of 
research funding provided to first authors of abstracts might encourage and enable 
time spent on developing a full publication, and, theoretically, the first author 
would devote the most time to writing up a full publication. In our study, 
compared with last authors, first authors were less likely to report industry as a 
primary affiliation (6.1% vs. 17.8%) and employment by a business with interest 
as a conflict of interest (4.3% vs. 13.9%). Yet compared with last authors, first 
authors, also reported receiving more financial support (18.8% vs. 9.0%) and gifts 
from industry in the past year (9.0% vs. 3.8%). The decision to ask an academic, 
not an industry employee, to serve as first author may be strategic in terms of 
influence on opinion leaders. Indeed first authors were slightly more frequently 
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affiliated with academic institutions than last authors (61.6% vs. 54.1%) in our 
study. It may be that academics are inclined to serve as abstract authors when they 
can be first and when publishing in full is an option. Research publications are 
generally important to advancement in academic careers, which might have 
motivated first authors affiliated with academic institutions to publish their results 
in full. Second, it is possible that a greater proportion of first authors than last 
authors in our study were junior researchers within academic institutions. 
Submission of abstracts is sometimes seen by junior researchers as means to attend 
conferences. Although we were unable to examine this directly because ARVO 
did not collect information from authors about their ranks/positions, we examined 
this indirectly by calculating the frequency with which first and last authors were 
removed in the full publications (assuming that removal of the first author would 
suggest that the first author might have been a junior researcher). The proportion 
of full publications that removed the first author (36%) was similar to the 
proportion that dropped the last author (41%), however, suggesting that it is 
unlikely that first authors were more often junior researchers. Third, it is possible 
that authors of abstracts in our study were different in some way from authors who 
have been examined in previous studies examining conflicts of interest. For 
example, only 33.0% and 28.1% of first and last authors respectively in our study 
reported at least one conflict of interest. These percentages have been reported to 
be higher in previous studies among academic investigators [26] and clinical 
practice guideline developers.[27] Fourth, it is possible that authors in our study 
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under-reported conflicts of interest. Although conflicts of interest disclosure was 
required by ARVO, it was self-reported by authors. 
 Findings from our interaction analysis suggest that, irrespective of statistical 
significance of results, conflicts of interest of the first author were associated with 
increased likelihood that authors went beyond presenting RCT results at the 
conference by publishing those results in full.  
 
Low rates of publication: Implications for researchers conducting clinical trials 
 Even after a long follow-up duration in our study, only 44.5% of abstracts 
were published in full. Publication is important for a number of reasons. At the 
very least, non-publication of RCT results is a waste of resources,[41-43] and 
worse, is arguably scientific misconduct.[19, 44, 45] RCT participants volunteer 
for clinical trials with the understanding that their participation advances science; 
non-publication is a violation of that understanding.[19] In addition, publication is 
important because, as we have demonstrated, there often is discordance between 
results presented in abstracts and in full publications. Assuming that when 
discordance exists between results reported in an abstract and a full publication, 
the full publication contains the more ‘valid’ results, it is important that 
researchers writing abstracts be more vigilant. Of course, this assumption does not 
always hold. In either event, researchers should be vigilant about presenting valid 
data at conferences. Further, low rates of publication and publication bias imply 
153 
that those summarizing the findings of RCTs are only able to access a biased 
subset of all RCTs.[19]  
 Even in the current era of increased awareness of the importance of open 
access to clinical trial data, full publication remains a key form of dissemination of 
study results. Studies published in full generally go through peer-review, reach a 
wider audience than abstracts, and contain greater detail and nuance than abstracts. 
This detail and nuance allows the readers of publications to critically appraise the 
results and interpret them in context.[8] Researchers must recognize the 
importance of publishing their results and overcome the barriers of lack of time 
and low priority.[17, 19, 37, 46, 47] Novel incentive structures for publication that 
go beyond monetary benefit and career advancement should be developed. 
 
Strengths of our study  
Our study has a number of strengths. First, we examined all abstracts of RCTs 
presented at the world’s largest research conference in ophthalmology (ARVO) 
over four consecutive years. To their credit, the organizers of ARVO required 
conflicts of interest disclosure by authors of all submitted abstracts. This allowed 
us a large sample size of 513 abstracts. For 400 abstracts (years 2002-2004), 
conflicts of interest information were available for each author, allowing us to 
separately examine conflicts of interest for first and last authors. Second, we did 
not selectively include abstracts based on clinical condition or type of 
intervention; we included all abstracts, provided participants were randomized. 
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Third, we had a long follow-up of the abstracts for full publication (maximum 
follow-up ranging from 110 to 146 months). This comfortably exceeds 48-60 
months, which is the time by which the majority of RCTs that would eventually be 
published are published.[19, 36] Fourth, we employed two strategies to identify 
full publications: electronic searching of multiple databases and contacting 
abstract authors via email. It is unlikely that we have missed a substantial number 
of full publications. 
 
Limitations to our study  
Our study also has a few potential limitations. First, only 9.6% of abstracts 
specified an outcome as “primary”. However, we a priori developed an algorithm 
to determine the main outcome for those abstracts that did not. Although this 
algorithm is likely consistent with how most readers of abstracts judge what is 
meant to be interpreted as the most important outcome, our definition may have 
influenced our findings related to the “main” outcome. Second, statistical 
significance of the main outcome was specified for only 228/513 abstracts 
(44.4%), and only 86/230 abstract/full publication pairs (37.4%) had the same 
main outcome at the same time-point, and reported statistical significance in both 
reports. Nevertheless, 86 pairs is a sizeable number for our conclusions. Third, a 
tradeoff for our study’s strength of a long duration of follow-up is that the 
abstracts we examined were presented at ARVO from 2001-2004, prior to 
initiatives such as compulsory registration of RCTs. Registration of RCTs at 
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ClinicalTrials.gov or at registries within the WHO International Clinical Trials 
Registry Platform (ICTRP) (http://www.who.int/ictrp/en/) could mitigate the 
impact of publication bias and outcome reporting bias in more recent abstract/full 
publication pairs. In addition, the CONSORT for Abstracts extension of the 
CONSORT Statement includes clear specification of the primary outcome as an 
essential checklist item.[48] This might have improved the reporting of outcomes 
in more recent abstract/full publication pairs.  
 
Conclusions 
 We have reported qualitative discordance or some amount of quantitative 
discordance in main outcome results for more than half of the abstract/full 
publication pairs. Researchers presenting at conferences should be vigilant about 
the accuracy of the results they present; and clinicians, patients, and systematic 
reviewers should be aware of these discordances. We have shown that the 
conflicts of interest most associated with full publication of abstracts are conflicts 
of interest of the abstract’s first author, irrespective of whether the results for the 
main outcome in the abstract were statistically significant, not statistically 
significant, or if statistical significance was not reported.  
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Box 4-1: Definitions for financial conflicts of interest as provided by ARVO 
 





This category includes funding received through 
employing institution support or from a not-for-profit or 
competing company, in the form of research 
funding/services (e.g. protein sequencing) at no cost, 






This category includes being an investor in a company or 
competing company other than through a mutual or 
retirement fund, which provides a product, service, 
process, or equipment that is the subject matter of the 
presentation/publication. 
 
Employee of a 
business with 
interest 
This category includes being an employee of a company or 
competing company with a business interest that is the 
subject matter of the presentation/publication. 
 
 
Consultant to a 
business with 
interest 
This category includes being/having been a consultant for 
a company or competing company with a business interest 






This category includes being an inventor/developer 
designated on a patent, patent application, copyright or 
trade secret, whether or not the patent, copyright, etc. is 
presently licensed or otherwise commercialized, which is 
the subject matter of the presentation/ publication or could 
be in competition with the technology described. 
 
Receiving at least 
one gift in the past 
year 
 
This category includes having received at least one gift in 
kind, honoraria, or travel reimbursement valued at over 
$1,000 in the last 12 months from a company or competing 
company which provides a product, service, process, or 








Table 4-1: RCT characteristics, author characteristics, and main outcome results of 
abstracts of RCTs presented at ARVO conferences during years 2001-2004, 
overall and by whether or not the abstract was published in full 
 















CHARACTERISTICS OF RCTs 
Presentation at ARVO N=513 N=283 N=230 
    Poster 418 (81.5) 239 (84.5) 179 (77.8) 
    Oral 95 (18.5) 44 (15.5) 51 (22.2) 
Funding N=513 N=283 N=230 
 Not reported 241 (47.0) 137 (48.4) 104 (45.2) 
 Reported 272 (53.0) 146 (51.6) 126 (54.8) 
 At least one funding source 158 (58.1) 73 (50.0) 85 (67.5) 
 Industry (pharmaceutical or other)* 56 (20.7) 22 (15.1) 34 (27.0) 
 Government* 71 (26.1) 31 (21.2) 40 (31.8) 
 Other* 59 (21.7) 30 (20.6) 29 (23.0) 
 No funding 114 (41.9) 73 (50.0) 41 (32.5) 
Number of centers N=513 N=283 N=230 
 Not reported 361 (70.4) 208 (73.5) 153 (66.5) 
 Reported 152 (29.6) 75 (26.5) 77 (33.5) 
 Single center 46 (30.3) 31 (41.3) 15 (19.5) 
 Multicenter 106 (69.7) 44 (58.7) 62 (80.5) 
CHARACTERISTICS OF FIRST AUTHORS  
Primary affiliation N=513 N=283 N=230 
 Not reported 8 (1.6) 7 (2.5) 1 (0.4) 





























Conflicts of interest (years 2002-2004 only) N=400 N=229 N=171 
 Not reported 0 (0.0) 0 (0.0) 0 (0.0) 
 Reported 400 (100.0) 229 (100.0) 171 (100.0) 
 At least one conflict of interest 132 (33.0) 65 (28.4) 67 (39.2) 
 F - Financial support* 75 (18.8) 31 (13.5) 44 (25.7) 
 I - Personal finance interest* 4 (1.0) 2 (0.9) 2 (1.2) 
 E - Employee of business with interest* 17 (4.3) 13 (5.7) 4 (2.3) 
 C - Consultant of business with interest* 43 (10.8) 23 (10.0) 20 (11.7) 
 P - Inventor/developer with patent* 8 (2.0) 5 (2.2) 3 (1.8) 
 R - Received gifts within the past year* 36 (9.0) 15 (6.6) 21 (12.3) 
 No conflict of interest 268 (67.0) 164 (71.6) 104 (60.8) 
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CHARACTERITICS OF LAST AUTHORS 
Primary affiliation N=513 N=283 N=230 
 Not applicable (abstract had one author) 28 (5.5) 8 (2.8) 20 (8.7) 
 Not reported 8 (1.6) 7 (2.5) 1 (0.4) 





























Conflicts of interest (years 2002-2004 only) N=400 N=229 N=171 
 Not applicable (abstract had one author) 21 (5.3) 8 (3.5) 13 (7.6) 
 Not reported 12 (3.0) 6 (2.6) 6 (3.5) 
 Reported 367 (91.7) 215 (93.9) 152 (88.9) 
 At least one conflict of interest 103 (28.1) 56 (26.1) 39 (25.7) 
 F - Financial support* 33 (9.0) 21 (9.8) 12 (7.9) 
 I - Personal finance interest* 1 (0.3) 1 (0.5) 0 (0.0) 
 E - Employee of business with interest* 51 (13.9) 28 (13.0) 23 (15.1) 
 C - Consultant of business with interest* 18 (4.9) 8 (3.7) 10 (5.9) 
 P - Inventor/developer with patent* 5 (1.4) 3 (1.4) 2 (1.2) 
 R - Received gifts within the past year* 14 (3.8) 7 (3.3) 7 (4.6) 
 No conflict of interest 272 (74.1) 159 (74.0) 113 (74.3) 
CONFLICTS OF INTEREST OF ANY AUTHOR 
Conflicts of interest N=513 N=283 N=230 
 Not reported 0 (0.0) 0 (0.0) 0 (0.0) 
 Reported 513 (100.0) 283 (100.0) 230 (100.0) 
 At least one conflict of interest 177 (34.5) 91 (32.2) 86 (37.4) 
 F - Financial support* 99 (19.3) 49 (17.3) 50 (21.7) 
 I - Personal finance interest* 6 (1.2) 4 (1.4) 2 (0.9) 
 E - Employee of business with interest* 76 (14.8) 40 (14.1) 36 (15.7) 
 C - Consultant of business with interest* 66 (12.9) 32 (11.3) 34 (14.8) 
 P - Inventor/developer with patent* 13 (2.5) 8 (2.8) 5 (2.2) 
 R - Received gifts within the past year* 55 (10.7) 23 (8.1) 32 (13.9) 
 No conflict of interest 336 (65.5) 192 (68.9) 144 (62.6) 
MAIN OUTCOME RESULTS 
Main outcome - Statistical significance N=513 N=283 N=230 
 Not reported 285 (55.6) 178 (63.9) 107 (46.5) 
 Reported  228 (44.4) 105 (37.1) 123 (53.5) 
 Not statistically significant  111 (48.7) 52 (49.5) 59 (48.0) 
 Statistically significant 117 (51.3) 53 (50.5) 64 (52.0) 
* More than one option could apply to each abstract. 
    ** Percentages are column percentages. Percentages in shaded rows are calculated with 
n reported as the denominator. 
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Table 4-2: Differences in authorship order comparing 230 conference abstracts 





No change in authorship 
 
28 (12.2) 
Middle authors changed, FIRST and LAST authors remained unchanged 
 
44 (19.1) 
LAST author changed, FIRST author remained unchanged 
 
52 (22.6) 
 LAST author moved to be a middle author 26  
 LAST author removed 16  
 Abstract had only one author, additional author(s) added    9  
 Abstract had multiple authors, only FIRST author remained   1  
FIRST author changed, LAST author remained unchanged 
 
33 (14.4) 
 FIRST author moved to be a middle author 25  
 FIRST author removed   8  
FIRST and LAST authors swapped positions 
 
6   (2.6) 
 No change in middle authors   1  
 With at least one change in middle authors   5  
LAST author changed to FIRST author 
 
15 (6.5) 
 FIRST author moved to be a middle author   8  
 FIRST author removed   7  
FIRST author changed to LAST author 
 15 (6.5) 
 LAST author moved to a middle author   7  
 LAST author removed   5  
 Abstract had only one author   3  
Both FIRST AND LAST author changed 
 37 (16.1) 
 Both authors moved to be middle authors 14  
 Both authors removed 18  
 FIRST author moved to be a middle author, LAST author removed   2  



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Abstracts presented at ARVO conferences in  
2001 (n=5061), 2002 (n=4802), 2003 (n=5248), and 2004 
(n=5610) 
  
Abstracts describing RCTs 
(n=545) 
Eligible abstracts describing RCTs 
(n=513) 









Figure 4-2: Kaplan-Meier plots showing time to full publication of abstracts 
of RCTs presented at ARVO conferences during years 2001-2004, overall 
and by various study characteristics, author characteristics, and statistical 
significance of main outcome results  
Figure 4-2a: All abstracts 
 
Figure 4-2b: By whether the RCT described in the abstract was funded, not 
funded, or funding was not reported  
    







































N=513 abstracts; Log rank p-value=0.021 
N=513 abstracts 
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Figure 4-2c: By number of centers in the RCT described in the abstract  
                                 
  
Legend: blue=multicenter; green=not reported; maroon=single center 
 
Figure 4-2d: By whether or not statistical significance of results for the main 
outcome was reported in the abstract 
  
  








































N=513 abstracts; Log rank p-value=0.006 
N=513 abstracts; Log rank p-value<0.001 
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Figure 4-2e: By statistical significance of results for the main outcome for 
abstracts in which this was reported 
 
              
Legend:  maroon=statistically significant; blue=not statistically significant 
Figure 4-2f: By whether or not the FIRST AUTHOR of the abstract reported at 
least one conflict of interest (abstracts from 2002-2004 only) 
  
Legend:  maroon=at least one conflict of interest; blue=no conflict of interest 













































N=228 abstracts; Log rank p-value=0.881 
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Figure 4-2g: By whether or not the LAST AUTHOR of the abstract reported at 
least one conflict of interest (abstracts from 2002-2004 only) 
   
Legend: maroon=at least one conflict of interest; blue=no conflict of interest 
Figure 4-2h: By whether or not the ANY AUTHOR of the abstract reported at 
least one conflict of interest (abstracts from 2002-2004 only) 
 
               
Legend: maroon=at least one conflict of interest; blue=no conflict of interest
N=400 abstracts; Log rank p-value=0.746 






































































































































































































































































































































































































































































   
   
   
   
   
   
   
   
   
   
   
   
   
   


























































































































































































































































































A key premise of evidence-based healthcare is that, in addition to clinical 
expertise and patient values, healthcare should be guided by sound clinical 
intervention research.[1] In turn, sound clinical intervention research relies on the 
use of the right outcomes dependably and without bias. We viewed the process of 
outcome use in a clinical intervention research study (clinical trial or systematic 
review) as having four main steps: (1) selection, (2) specification, (3) data 
collection and analysis, and (4) outcome reporting. We designed this dissertation 
with three specific aims addressing important questions related to these steps. In 
this chapter, we summarize results and implications for each specific aim, make 
overall conclusions, and suggest future directions.  
 
Aim 1: Use social network analysis methods to (a) understand patterns of co-
occurrence of outcomes in systematic reviews of HIV/AIDS; and (b) identify 
outcomes that are central to the network of outcomes examined in systematic 
reviews of HIV/AIDS. 
 Drawing from the toolbox of social network analysis, we tested the novel 
application of those methods to systematically identify central outcomes from 
among the 294 unique outcomes in all 140 Cochrane systematic reviews in the 
field of HIV/AIDS. These central outcomes could be used to develop core 
outcome sets, which are valuable for the process of selecting outcomes for clinical 
intervention research.  
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Systematic reviews are an excellent starting point for identifying central 
outcomes. Existing systematic reviews in a field, when considered together, 
appraise a large portion of the evidence, much of it from clinical trials. Social 
network analysis capitalizes on the underlying affinity (or repulsion) between 
outcomes that leads to outcomes co-occurring (or not) in the same systematic 
review or clinical trial. Generally, the seven most central outcomes were not 
exactly the same as the seven most frequent outcomes, both overall as well as 
within topic subgroups of reviews defined by Cochrane. Using the field of 
HIV/AIDS as an example, we have shown that if frequency were used as the sole 
determinant for defining a core outcome set, certain important outcomes (such as 
adverse events) would be missed. Central outcomes and frequent outcomes should 
be used in tandem when selecting outcomes for a core outcome set.  
 
Aim 2: Assess the completeness of pre-specification and comparability of 
outcomes in systematic reviews addressing four common eye conditions. 
 In clinical intervention research, pre-specification of outcomes occurs at the 
time the protocol is written, and specification of outcomes occurs when the results 
are reported. We examined all 57 Cochrane systematic review protocols 
addressing four common eye conditions and found that, if outcome pre-
specification is judged using recommended standards for clinical trials, pre-
specification of outcomes in these systematic review protocols is largely 
incomplete. We used a five-element framework (domain, specific measurement, 
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specific metric, method of aggregation, and time-points) to examine each outcome 
for completeness.  
It is important to note that pre-specification is not an end in itself. Rather, it 
is important for two reasons. First, pre-specification helps ensure that the 
outcomes are measured and analyzed in an unbiased manner during the clinical 
trial. In our sample of Cochrane systematic review protocols, we are unable to rule 
out that incomplete pre-specification might have led the systematic reviewers to 
measure and/or analyze the outcomes differently or at different time-points than 
originally planned. If, indeed, these decisions were based on the systematic review 
results, it raises concerns about the validity of the analyses. Second, pre-
specification of outcomes helps minimize the potential for outcome reporting bias. 
When the elements of outcomes pre-specified (i.e., before the study) and specified 
(i.e., when the study is reported) differ, this raises concerns about outcome 
reporting bias. The largely incomplete outcome pre-specification meant that we 
were unable to rule out that there might have been outcome reporting bias in these 
systematic reviews.  
We encourage systematic reviewers and clinical trialists to incorporate all 
five elements when pre-specifying outcomes for their research, so that the 
subsequent steps of outcome use (data collection and analysis and outcome 
reporting) are conducted without bias.  
Because of the incomplete pre-specification of outcomes, we were also 
unable to assess conclusively the comparability in individual outcome elements 
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across the various protocols per condition. However, we observed variation in 
specific metrics and methods of aggregation. 
 
Aim 3: Evaluate, using randomized controlled trials in ophthalmology, (a) the 
agreement in reported main outcome results comparing abstracts and their 
corresponding full publications; and (b) the association between author conflicts 
of interest and full publication of results presented in abstracts. 
 We examined all 513 abstracts describing randomized controlled trials that 
were presented at the 2001-2004 Association for Research in Vision and 
Ophthalmology (ARVO) annual conferences, and followed them longitudinally 
for whether or not they were published in full through 2013. When we compared 
abstracts that were published in full with its corresponding full publications, we 
found that there was exact agreement in reported results for the main outcome in 
less than half of the abstract/full publication pairs. There was some amount of 
quantitative discordance in almost half the pairs, and qualitative discordance in 
1/12 pairs. We also found that, irrespective of main outcome results, the conflicts 
of interest most associated with full publication of abstracts of RCTs are conflicts 
of interest of the abstract’s first author (specifically, receiving financial support 





Overall conclusions and future directions 
 The results we present in this dissertation provide numerous causes for 
concern, and we propose suggestions for ways forward. 
 The clinical research community is interested in finding the best method to 
develop core outcome sets for intervention research. A variety of semi-structured 
group discussions (e.g., workshops), unstructured group discussions, literature 
reviews, and surveys have been used, but no best practice method to do so 
currently exists.[2] Our results using social network analysis explored a new 
application to assessment of possible outcomes for a core outcome set (i.e., co-
occurrence of outcomes in systematic reviews), leading to the identification of 
central outcomes for clinical intervention research. We propose that this method 
be examined in other fields and, if found to be valuable in developing core 
outcome sets, subsequently implemented more widely.   
Specific questions remain. First, it is unclear to what extent the most central 
outcomes in systematic reviews (as identified in Aim 1) reflect the most central 
outcomes in clinical trials. It is likely that the number of outcomes examined in the 
clinical trials that were included in the systematic reviews we examined is greater 
than the number of outcomes examined in the systematic reviews alone. However, 
we currently do not know about the patterns of co-occurrence of outcomes among 
the clinical trials and between the clinical trials and the systematic reviews. A 
comparison of the social networks of outcomes in clinical trials and systematic 
reviews, and the overlap between the two lists of central outcomes obtained 
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therefrom, would contribute to our understanding of whether and to what extent 
core outcome sets would differ based on the source used for identifying central 
outcomes. It is possible, even likely, that the lists of the most central outcomes in 
systematic reviews and clinical trials would differ, given the different purposes of 
these two study designs (clinical trials are more focused on clinically-relevant 
outcomes, while systematic reviews are more focused on policy-relevant 
outcomes). Second, we found that the lists of the most central outcomes and the 
most frequent outcomes tended to differ more in networks of outcomes that were 
more centralized (higher centralization values, see Chapter 2). This suggests that 
the social network analysis approach might be more valuable in more centralized 
networks compared to less centralized networks (i.e., networks in which the 
overlap between central and frequent outcomes is greater). Future studies in other 
fields should explore this finding further. If it is indeed to found to be generally 
true that the social network analysis method might be more valuable in more 
centralized networks, the degree of centralization could be used to determine 
whether a complete social network analysis of that network is worth the resources 
spent in conducting and interpreting the analysis. 
 Our results related to outcome specification also provide cause for concern. 
Incomplete pre-specification of outcomes suggests that we are unable to rule out 
the possibility of bias in the data collection and analysis in these systematic 
reviews. Incomplete specification also hinders comparability in outcomes across 
systematic reviews (or clinical trials) addressing similar interventions in a field. 
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That systematic reviewers do not completely pre-specify outcomes they will 
examine is worrisome because of the potential for outcome reporting bias. This 
could occur if the systematic reviewer’s choice of outcomes is influenced by the 
outcomes examined (and the results) in the clinical trials that would be included in 
the systematic review. Future research should evaluate whether the results of 
outcomes examined in the clinical trials influence choice of outcomes in 
systematic reviews.  
We encourage (1) organizations that provide methodological and reporting 
guidance for researchers conducting systematic reviews and clinical trials (e.g., 
Cochrane, Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA), and Consolidated Standards of Reporting Trials (CONSORT)), to 
incorporate the five-element framework for outcome specification into guidance 
documents; and (2) journal editors and peer reviewers to insist on appropriate 
reporting of all outcomes using this framework. 
 Our results related to discrepancies in main outcome results between 
conference abstracts and their corresponding full publications are a cause for 
concern. Our results indicate that more than half of abstract/full publication pairs 
have some form of discordance for the main outcome. We encourage all clinical 
trialists to be vigilant about reporting dependable clinical trial data, whatever the 
forum of presentation. While we support the inclusion of results from abstracts in 
systematic review, we encourage systematic reviewers to be aware of the fact that 
183 
discordances can occur, and to conduct the appropriate sensitivity analyses to 
examine the robustness of their findings. 
Another concern that our results raise is that, irrespective of statistical 
significance of study results, monetary gain (conflicts of interest) might determine 
whether authors of a conference abstract describing a randomized controlled trial 
might publish the abstract in full. The first author’s conflict of interest appears to 
matter most, specifically, receiving financial support or gifts from industry within 
the past year. We explored certain potential reasons why these findings might have 
been observed. First, compared with last authors, first authors were less often 
employed by industry and more often affiliated with academic institutions, where 
publications generally help towards career advancement. Second, compared with 
last authors, first authors more often received financial support and gifts from 
industry, which might have specifically encouraged first authors to devote the 
necessary time and resources to publish. Third, it is possible that the authors in 
other study were different from authors in previous studies; for example, the 
proportion of authors reporting at least one conflict of interest was lower than 
what has been documented in previous studies.[3, 4] 
Finally, less than half of the abstracts we included were published in full. 
Because of the importance of publication and the commitment made by clinical 
trialists to clinical trial participants to advance science, we encourage all clinical 
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studies and, more broadly, in developing and improving methods for systematic 
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publications address methodology for comparative effectiveness research. My 
ongoing research involves selecting outcomes for clinical research using state-of-
the-art methods.  
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My teaching experience covers the breadth of epidemiology, ranging from 
evidence generation (observational studies and clinical trials) to evidence 
synthesis (systematic reviews and meta-analyses) and policy (translational 
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